Compositions and methods for modulating activated t cell nuclear factor (NFAT) activity of t cells
By using herbal compositions of scutellaria baicalensis, licorice, peony and jujube, the problem of regulating NFAT activity and enhancing the effect of immunotherapy is solved, and the goal of improving T cell activation and cancer treatment effect is achieved.
Patent Information
- Application Number
- CN202380024424.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-03-01
- Filing Date
- 2023-02-28
- Publication Date
- 2024-11-08
AI Technical Summary
The prior art lacks in regulating the activity of activated T cells nuclear factor (NFAT), especially in the treatment of inflammatory bowel disease and various types of cancer.
Using herbal compositions including scutellaria baicalensis, licorice, peony and jujube, the extract or fractions thereof are administered orally, the phosphorylation of downstream cascade proteins of T cell receptors is induced and the activity of SH2-containing phosphatase 2 (SHP2) is inhibited, and the activity of SH2-containing phosphatase 2 (SHP2) is enhanced. and the efficacy of immune checkpoint blocking therapy.
It significantly improved the activation of T cells and the effect of immunotherapy, enhanced the effectiveness of cancer treatment, and improved the vaccination effect.
Smart Images

Figure CN118922200A_ABST
Abstract
Description
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS
[0002] This application claims priority under 35 USC §119(e) to U.S. Provisional Application No. 63 / 315,163, filed on March 1, 2022, which is hereby incorporated by reference in its entirety.
[0003] Sequence Listing
[0004] This application contains a sequence listing in XML format and is incorporated herein by reference in its entirety. The XML file was created on February 15, 2023, named 047162_7355WO1_SequenceListing.xml, and has a size of 3000 bytes. Background Art
[0005] Nuclear factor of activated T cells (NFAT) is a family of transcription factors consisting of five members, NFATc1, NFATc2, NFATc3, NFATc4 and NFAT5. It is well known that NFAT is used to regulate immune responses. At least one member of the NFAT family is expressed in most cells of the immune system. In addition, it is also known that NFAT is involved in the development of the heart, skeletal muscle and nervous system. NFAT is being studied as a drug target for several different diseases and disorders, for example, inflammatory bowel disease and several types of cancer. In addition, there is an unmet need in the art in developing compositions and methods for regulating NFAT activity. The present invention addresses this need. Summary of the invention
[0006] In one aspect, the present invention provides a method of enhancing nuclear factor of activated T cells (NFAT) activity and / or restoring suppressed NFAT activity in a subject in need thereof, wherein the method comprises administering to the subject a therapeutically effective amount of at least one herbal composition selected from the group of herbal compositions described elsewhere herein.
[0007] In another aspect, the present invention provides a method of enhancing the efficacy of chimeric antigen receptor T cell (CAR T) immunotherapy in a subject, wherein the method comprises administering to the subject a therapeutically effective amount of at least one herbal composition selected from the group of herbal compositions described elsewhere herein.
[0008] In yet another aspect, the present invention provides a method of enhancing the efficacy of immune checkpoint blockade therapy in a subject, wherein the method comprises administering to the subject a therapeutically effective amount of at least one herbal composition selected from the group of herbal compositions described elsewhere herein.
[0009] In yet another aspect, the present invention provides a herbal composition for use in modulating NFAT activity in T cells in a subject in need thereof, wherein the herbal composition is selected from the group of compositions described elsewhere herein.
[0010] In yet another aspect, the present invention provides a method of enhancing the effectiveness of a vaccine in a subject, wherein the method comprises administering to the subject a therapeutically effective amount of at least one herbal composition selected from the group of herbal compositions described elsewhere herein.
[0011] In certain embodiments, the herbal composition is at least one selected from the group consisting of:
[0012] (a) herbal extract PHY906, which comprises herbal extracts of Scutellaria baicalensis (S), Glycyrrhiza uralensis (G), Paeonia lactiflora (P) and Ziziphus jujuba (Z), fractions thereof or any active chemical substance present in the herbal extract or its fractions;
[0013] (b) an herbal extract of S, a fraction thereof or any active chemical substance present in an herbal extract or a fraction thereof;
[0014] (c) herbal extracts including extracts of S, fractions thereof or any active chemical substance present in herbal extracts or fractions thereof;
[0015] (d) the herbal extract of G, its fractions or any active chemical substance present in the herbal extract or its fractions;
[0016] (e) herbal extracts including extracts of G, fractions thereof or any active chemical substance present in herbal extracts or fractions thereof;
[0017] (f) an herbal extract of P, a fraction thereof or any active chemical substance present in an herbal extract or a fraction thereof; and
[0018] (g) herbal extracts including extracts of P, fractions thereof or any active chemical substance present in the herbal extract or its fractions.
[0019] (h) an herbal extract of Z, a fraction thereof or any active chemical substance present in an herbal extract or a fraction thereof; and
[0020] (i) an herbal extract comprising an extract of Z, a fraction thereof or any active chemical substance present in the herbal extract or its fraction.
[0021] In certain embodiments, the active chemical substance in the herbal extract of S or its fraction is at least one selected from baicalin A 7-O-β-D-glucuronide, baicalin, baicalin A, baicalin, isomers of baicalin, chrysanthemumin 6-C-arabinoside 8-C-glucoside, actiside, baicalein I 2'-O-glucoside and chrysanthemum.
[0022] In certain embodiments, the active chemical substance in the herbal extract of G or its fraction is at least one selected from the group consisting of liquiritigenin, isoliquiritigenin, liquiritigenin, isoliquiritigenin, licoricechalcone A and glycyrrhizic coumarin.
[0023] In certain embodiments, the active chemical substance in the herbal extract of P or its fraction is at least one selected from gallic acid, 4-o-methylpaeoniflorin, 4-o-methylpaeoniflorin isomers, 6′-O-galloylpaeoniflorin, paeoniflorin and paeoniflorin.
[0024] In certain embodiments, the herbal composition is administered orally to a subject.
[0025] In certain embodiments, the herbal composition is formulated as one selected from a pill, a tablet, a capsule, a decoction, a tea, a concentrate, a lozenge, a liquid, drops, and a caplet.
[0026] In certain embodiments, the therapeutically effective amount of the herbal composition is from about 20 mg / day to about 2 g / day.
[0027] In certain embodiments, the therapeutically effective amount of the herbal composition is about 1,600 mg / day.
[0028] In certain embodiments, the method induces phosphorylation of proteins in the downstream cascade of the T cell receptor (TCR) and inhibits the activity of SH2-containing phosphatase 2 (SHP2).
[0029] In certain embodiments, the herbal composition is administered at a time selected from before, simultaneously with, and after administration of immune checkpoint inhibitor therapy or chimeric antigen receptor T (CAR T) cell therapy or a vaccine.
[0030] In certain embodiments, the immune checkpoint inhibitor therapy comprises administering at least one immune checkpoint inhibitor selected from ipilimumab, pembrolizumab, nivolumab, durvalumab, avelumab, dotalimumab-gxly, cemiplizumab-rwlc, toripalimab, carrelizumab, tislelizumab, penampalimumab, sepalizumab, sintilimab, and atezolizumab.
[0031] In certain embodiments, the method is advantageous for at least one selected from the group consisting of:
[0032] a) Enhance the efficacy of CAR T cell therapy,
[0033] b) enhance the efficacy of immune checkpoint inhibitor therapy, and
[0034] c) Enhance the effectiveness of vaccines.
[0035] In certain embodiments, the method is used for cancer chemoprevention.
[0036] In certain embodiments, the composition further comprises a pharmaceutically acceptable carrier.
[0037] In certain embodiments, the subject is a mammal. In certain embodiments, the subject is a human subject. BRIEF DESCRIPTION OF THE DRAWINGS
[0038] The following detailed description of specific embodiments of the present invention will be better understood when read in conjunction with the accompanying drawings. In order to illustrate the present invention, specific embodiments are shown in the drawings. However, it should be understood that the present invention is not limited to the precise arrangements and tools of the embodiments shown in the drawings.
[0039] Figures 1A-1F The effects of YIV-906 and its constituent herbs: Licorice (G), Peony (P), Scutellaria (S), and Ziziphus (Z) in the absence or presence of Staphylococcal superantigen E (SEE) on NFAT-mediated transcriptional activity in Jurkat cells incubated with wild-type Raji cells were compared. Figure 1A ) and SEE( Figure 1B ) on the NFAT-mediated transcriptional activity of Jurkat cells incubated with Raji cells. In addition, the two herbal combinations were shown in the absence of SEE ( Figure 1C ) and SEE( Figure 1D ) on the NFAT-mediated transcriptional activity of Jurkat cells incubated with Raji cells. In addition, deletion of one of the herbs YIV-906, -G, -P, -S, and -Z was shown in the absence of SEE ( Figure 1E ) and SEE( Figure 1F ) on the NFAT-mediated transcriptional activity of Jurkat cells incubated with Raji cells. Equal amounts of the aqueous extract (up to 320 ug / ml) were added to Jurkat cells stably transfected with the NFAT luciferase reporter gene with Raji cells in the absence or presence of 10 ng / ml of Staphylococcus superantigen E (SEE), and luciferase activity was measured 24 hours later.
[0040] Figures 2A-2F The effects of YIV-906 and its constituent herbs: Licorice (G), Paeonia lactiflora (P), Scutellaria baicalensis (S), and Ziziphus jujuba (Z) in the absence or presence of SEE on NFAT-mediated transcriptional activity in PD1-overexpressing Jurkat cells incubated with PD-L1-overexpressing Raji cells are shown. Figure 2A ) and SEE( Figure 2B ) on the NFAT-mediated transcriptional activity of Jurkat-PD1 cells incubated with Raji-PD-L1 cells. In addition, the two herbal combinations were shown in the absence of SEE ( Figure 2C ) and SEE( Figure 2D ) on the NFAT-mediated transcriptional activity of Jurkat-PD1 cells incubated with Raji-PD-L1 cells. In addition, deletion of one of the herbs YIV-906, -G, -P, -S, and -Z was shown to have an effect on the NFAT-mediated transcriptional activity of Jurkat-PD1 cells incubated with Raji-PD-L1 cells in the absence of SEE ( Figure 2E ) and SEE( Figure 2F ) on the NFAT-mediated transcriptional activity of Jurkat-PD1 cells incubated with Raji-PD-L1 cells. Equal amounts of the aqueous extract (up to 320 ug / ml) were added to Jurkat-PD1 cells stably transfected with the NFAT luciferase reporter gene together with Raji-PD-L1 cells in the absence or presence of SEE 10 ng / ml, and luciferase activity was measured after 24 hours.
[0041] Figures 3A-3D is a graph showing the effect of YIV-906 on the T activation marker CD69 of Jurkat cells overexpressing PD1 when incubated with Raji cells without or with PD-L1 overexpression. shows the median fluorescence ( Figure 3A ) and groups ( Figure 3B ). Also shown is the effect of YIV-906 on the median fluorescence of Jurkat PD1 cells when incubated with PD-L1-overexpressing Raji cells in the absence or presence of SEE antigen ( Figure 3C ) and groups ( Figure 3D). The aqueous extract of YIV-906 (up to 320ug / ml) was added to Jurkat-PD1 cells and wild-type or PD-L1 overexpressing Raji cells without or with SEE 3ng / ml, 10ng / ml, for 24 hours. The expression of CD69 was determined by flow cytometry, where FITC-conjugated anti-CD69 was used to determine the expression of CD69 protein on the Jurkat cell membrane, and PE-conjugated anti-PD1 was used to screen Jurkat PD1 cells from the mixture of Jurkat / Raji cells.
[0042] Figures 4A-4D The effective herbs selected from YIV-906 are shown: S( Figure 4A )、P( Figure 4B )、Z( Figure 4C ) and G( Figure 4D The chemical structures of pure compounds of ) were used to study their effects on NFAT activity in Jurkat cells.
[0043] Figures 5A-5D The effects of S compounds on NFAT-mediated transcriptional activity of PD1-overexpressing Jurkat cells incubated with PD-L1-overexpressing Raji cells in the absence or presence of SEE are shown. Figure 5A ) and SEE( Figure 5B ) in the absence of SEE ( Figure 5C ) and SEE( Figure 5D ) in the absence or presence of 10 ng / ml of Staphylococcus superantigen E (SEE), the S compound was added to Jurkat-PD1 cells stably transfected with the NFAT luciferase reporter gene together with wild-type Raji cells or Raji-PD-L1 cells at up to 40 uM, and the luciferase activity was measured after 24 hours.
[0044] Figure 5E-5H The effect of compound P on NFAT-mediated transcriptional activity of PD1-overexpressing Jurkat cells incubated with PD-L1-overexpressing Raji cells in the absence or presence of Staphylococcal superantigen E (SEE). Figure 5E ) and SEE( Fig. 5F) in the absence of SEE ( Figure 5C ) and SEE( Figure 5H Effect of P compound on NFAT-mediated transcriptional activity of Jurkat-PD1 cells incubated with Raji-PD-L1 cells in the absence or presence of SEE 10 ng / ml. P compound up to 160 uM was added to Jurkat-PD1 cells stably transfected with NFAT luciferase reporter gene together with wild-type Raji cells or Raji-PD-L1 cells, and luciferase activity was measured after 24 hours.
[0045] Figures 6A-6D The effects of G and Z compounds on NFAT-mediated transcriptional activity of PD1-overexpressing Jurkat cells incubated with wild-type Raji or PD-L1-overexpressing Raji cells in the absence or presence of SEE are shown. Fig. 6A ) and SEE( Figure 6B ) in the absence of SEE ( Figure 6C ) and SEE( Fig.6D ) in the absence or presence of 10 ng / ml of Staphylococcus superantigen E (SEE), the effect of S compound on NFAT-mediated transcriptional activity of Jurkat-PD1 cells incubated with Raji-PD-L1 cells. Up to 40 uM of G and Z compounds were added to Jurkat-PD1 cells stably transfected with NFAT luciferase reporter gene together with wild-type Raji cells or Raji-PD-L1 cells, and luciferase activity was measured after 24 hours.
[0046] Figures 7A-7F The effects of YIV-906, S and S compounds on NFAT-mediated transcriptional activity in Jurkat-PD1 cells and T cell receptor-αβ (TCRαβ) knockout Jurkat-PD1 cells are illustrated. The expression of FITC-conjugated anti-TCRαβ and flow cytometry in Jurkat-PD1 ( Fig. 7A ) and Jurkat-PD1 TCRαβ knockout cells ( Figure 7B ). It shows that YIV-906 ( Figure 7C )、S( Figure 7C ) and S compounds ( Fig.7D) on the NFAT-mediated transcriptional activity of Jurkat-PD1 cells. Fig. 7E )、S( Fig. 7E ) and S compounds ( Figure 7F ) on NFAT-mediated transcriptional activity in Jurkat-PD1 TCRαβ knockout cells.
[0047] Figures 8A-8D It shows YIV-906( Fig. 8A ), single herb( Fig. 8A )、YIV-906 fractions ( Figure 8B )、P( Figure 8C ) and S( Fig.8D ) on the phosphorylation of proteins in the T cell receptor signaling cascade including Lck, Fyn, Zap70, LAT and Pyk2. YIV-906, S and P were fractionated using a C18 solid phase extraction column by eluting with water and increasing percentages of acetonitrile / methanol (A / M). All eluted fractions were dried and reconstituted with water to an equivalent concentration of 100 mg / ml. Fig. 8A ), single herb( Fig. 8A )、YIV-906 fractions ( Figure 8B )、P( Figure 8C ) and S( Fig.8D ) Jurkat cells were treated with an equivalent dose of 320 ug / ml for 45 min. Western blot analysis was performed using specific antibodies to determine protein phosphorylation. Protein loading was normalized using GAPDH.
[0048] Figures 9A-9B The P( Fig.9A ) and S( Fig. 9B Chemical identification of fractions of ) and their effects on protein phosphorylation of Lck, Zap70, Lat, Fyn / Src, Pyk2. Equivalent concentration, 10 mg / ml, was used for LC-MS analysis. Equivalent concentration, 320 ug / ml, 45 minutes, was used to treat Jurkat cells for western blot analysis. Chemicals identified based on their mass and the mass of their fragments (putative) are listed under each fraction. Unidentified chemicals are not listed in this figure. Fractions that can induce phosphorylation of specific proteins are marked with red upward arrows.
[0049] Fig.10 The effects of S and P compounds on the phosphorylation of proteins of the T cell receptor signaling cascade including Lck, Fyn, Zap70, LAT and Pyk2 are shown. Jurkat cells were treated with S and P compounds for 45 minutes. Western blot analysis was performed using specific antibodies to determine the phosphorylation of proteins.
[0050] Figures 11A-11D Graph illustrating the effects of YIV-906 and its components on SHP2 activity. Fig.11A Shown are the effects of YIV-906 on SHP2 activity without or with β-glucuronidase treatment. Fig. 11B Shown are the effects of YIV-906 and its constituent herbs: G, P, S and Z on SHP2 activity at 1 mg / ml. Fig. 11C The effect of 40 uM of G compound on SHP2 activity is shown. Fig.11D The effect of 40 uM of S compound on SHP2 activity is shown. The activity of SHP2 was determined by p-nitrophenyl phosphate (pNPP) colorimetric method, where pNPP was used as substrate and the activity of SHP2 was reflected by the increase of absorbance at 450 nm.
[0051] Figures 12A-12B The graph shows that at 10 ng / ml ( Fig. 12A ) or 30ng / ml( Fig. 12B ) Staphylococcal superantigen E (SEE), the effect of the combination of YIV-906 and nivolumab on NFAT-mediated transcriptional activity of PD1-overexpressing Jurkat cells incubated with wild-type Raji or PD-L1-overexpressing Raji cells. Before measuring luciferase activity, Jurkat-PD1 cells were treated with biosimilar nivolumab 18ug / ml for 24 hours, and then YIV-906 160ug / ml water extract and wild-type Raji cells or Raji-PD1-L1 cells were added to Jurkat PD1 cells for another 24 hours.
[0052] Figures 13A-13F The effects of YIV-906, S and S compounds on the transcriptional activity of Jurkat cells mediated by NFAT triggered by the interaction of the chimeric antigen receptor (CAR-CD19-CD3z) on Jurkat cells and CD19 on Raji cells are shown. Fig.13A )、S( Fig.13A ) and S compounds ( Fig. 13B ) on the NFAT-mediated transcriptional activity of Jurkat-PD1 cells carrying a chimeric antigen receptor (CAR-CD19-CD3z). Also shown is the effect of YIV-906 ( Fig. 13C )、S( Fig. 13C ) and S compounds ( Fig.13D) on the NFAT-mediated transcriptional activity of Jurkat-PD1 cells carrying a chimeric antigen receptor (CAR-CD19-CD3z) and incubated with wild-type Raji cells. Fig.13E )、S( Fig.13E ) and S compounds ( Fig.13F ) on the NFAT-mediated transcriptional activity of Jurkat-PD1 cells carrying a chimeric antigen receptor (CAR-CD19-CD3z) and incubated with Raji-PD-L1 cells. YIV-906, aqueous extracts of S (up to 320ug / ml) and 40uM of S compound were added to Jurkat-PD1-CAR-CD19 cells stably transfected with the NFAT luciferase reporter gene together with wild-type Raji cells or Raji-PD-L1 cells, and luciferase activity was measured after 24 hours. DETAILED DESCRIPTION
[0053] Reference will now be made in detail to certain embodiments of the disclosed subject matter.While the disclosed subject matter will be described in conjunction with the enumerated claims, it will be understood that the enumerated subject matter is not intended to limit the claims to the disclosed subject matter.
[0054] definition
[0055] As used herein, each of the following terms has the meaning associated with it in this section.
[0056] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the present disclosure belongs. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present disclosure, exemplary methods and materials are described.
[0057] Generally, the nomenclature used herein and the laboratory procedures in pharmacology, natural product chemistry, and organic chemistry are those well known and commonly employed in the art.
[0058] As used herein, the articles "a" and "an" refer to one or more (ie, at least one) of the grammatical object of the article. By way of example, "an element" means one element or more than one element.
[0059] As used herein, the term "about" can allow a value or range to vary to a certain degree, for example, within 10%, 5% or 1% of a stated value or the stated limit of a range, and includes the exact stated value or range.
[0060] As used herein, the term "substantially" refers to a majority or majority, such as at least about 50%, 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.9%, 99.99% or at least about 99.999% or more or 100%. As used herein, the term "substantially free of" can refer to having no or only trace amounts, such that the amount of material present does not affect the material properties of the composition including the material, such that the material in the composition is from about 0 wt % to about 5 wt %, or from about 0 wt % to about 1 wt %, or about 5 wt % or less, or less than, equal to or more than about 4.5 wt %, 4, 3.5, 3, 2.5, 2, 1.5, 1, 0.9, 0.8, 0.7, 0.6, 0.5, 0.4, 0.3, 0.2, 0.1, 0.01 or about 0.001 wt % or less. The term "substantially free" can mean having trace amounts such that the material in the composition is from about 0 wt % to about 5 wt %, or from about 0 wt % to about 1 wt %, or about 5 wt % or less, or less than, equal to or more than about 4.5 wt %, 4, 3.5, 3, 2.5, 2, 1.5, 1, 0.9, 0.8, 0.7, 0.6, 0.5, 0.4, 0.3, 0.2, 0.1, 0.01, or about 0.001 wt % or less, or about 0 wt %.
[0061] As used herein, the term "cancer" is defined as a disease characterized by the rapid and uncontrolled growth of abnormal cells. Cancer cells can spread locally or to other parts of the body through the blood and lymphatic system. Examples of various cancers include, but are not limited to, bone cancer, breast cancer, prostate cancer, ovarian cancer, cervical cancer, skin cancer, pancreatic cancer, colorectal cancer, kidney cancer, liver cancer, brain cancer, lymphoma, leukemia, lung cancer, etc.
[0062] In one aspect, the terms "co-administered" and "co-administration" with respect to a subject refer to administering a compound and / or composition of the present disclosure to a subject together with a compound and / or composition that can also treat or prevent a disease or disorder contemplated herein. In certain embodiments, the co-administered compounds and / or compositions are administered alone, or in any combination as part of a monotherapy approach. The co-administered compounds and / or compositions can be formulated as a mixture of solids and liquids in any combination under various solid, gel, and liquid formulations, as well as formulated as solutions.
[0063] As used herein, the term "extract" refers to a concentrated preparation or solution of a compound or drug derived from a natural source such as an herb or other plant material. The extract can be prepared by a variety of processes, including soaking the herb in a solution, or drying and grinding the herb into a powder and dissolving the powder in a solution. After a certain amount of the desired compound is dissolved in the solution, the extract can be further concentrated by removing part of the solvent. The extract can also be filtered (strain) or centrifuged to remove any solid matter in the solution.
[0064] As used herein, the term "inhibit" refers to reducing the expression, stability, function or activity of a molecule, reaction, interaction, gene and / or protein by a measurable amount, or completely preventing it. An inhibitor refers to a compound that, for example, binds to, partially or completely blocks stimulation, reduces, prevents, delays activation, inactivates, desensitizes or downregulates the stability, expression, function and activity of a protein or gene, such as an antagonist.
[0065] As used herein, the term "pharmaceutical composition" or "composition" refers to a mixture of at least one compound useful in the present disclosure and a pharmaceutically acceptable carrier. The pharmaceutical composition facilitates administration of the compound to a subject.
[0066] As used herein, the term "pharmaceutically acceptable" refers to a substance, such as a carrier or diluent, that does not impair the biological activity or properties of the compounds useful in the present disclosure and is relatively nontoxic, i.e., the substance can be administered to a subject without causing adverse biological effects or interacting in a deleterious manner with any ingredient of the composition in which it is contained.
[0067] As used herein, the term "pharmaceutically acceptable carrier" refers to a pharmaceutically acceptable substance, composition or vehicle that is involved in carrying or transporting a compound useful in the present disclosure to a subject so that it can perform its intended function, such as a liquid or solid filler, stabilizer, dispersant, suspending agent, diluent, excipient, thickener, solvent or encapsulating material. Typically, such a construct is carried or transported from one organ or part of the body to another. Each carrier must be "acceptable" in the sense of being compatible with the other ingredients of the formulation, including the compounds useful in the present disclosure, and not causing harm to the subject. Some examples of substances that can be used as pharmaceutically acceptable carriers include: sugars such as lactose, glucose, and sucrose; starches such as corn starch and potato starch; cellulose and its derivatives such as sodium carboxymethylcellulose, ethylcellulose, and cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients such as cocoa butter and suppository waxes; oils such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil, and soybean oil; glycols such as propylene glycol; polyols such as glycerol, sorbitol, mannitol, and polyethylene glycol; esters such as ethyl oleate and ethyl laurate; agar; buffers such as magnesium hydroxide and aluminum hydroxide; surfactants; alginic acid; pyrogen-free water; isotonic saline; Ringer's solution; ethanol; phosphate buffered saline; and other nontoxic, compatible substances used in pharmaceutical formulations. As used herein, "pharmaceutically acceptable carriers" also include any and all coatings, antibacterial and antifungal agents, and absorption delaying agents, etc., that are compatible with the activity of the compounds useful in the present disclosure and that are physiologically acceptable to the subject. Supplementary active compounds may also be incorporated into the composition. "Pharmaceutically acceptable carriers" may further include pharmaceutically acceptable salts of compounds useful in the present disclosure. Other additional ingredients that may be included in the pharmaceutical compositions used in the practice of the present disclosure are known in the art, such as those described in Remington's Pharmaceutical Sciences (Genaro, Ed., Mack Publishing Co., 1985, Easton, PA), which is incorporated herein by reference.
[0068] As used herein, the term "YIV-906" refers to an herbal composition comprising Glycyrrhiza uralensis (G), Peony Root (P), Scutellaria baicalensis (S) and Ziziphus jujuba (Z). YIV-906 may refer to, for example, a specific composition comprising S, G, P and Z in a ratio of 3:2:2:2 prepared according to standard operating procedures, and in some embodiments comprises hot water extracts of S, P, G and Z.
[0069] As used herein, the terms "prevent," "prevention," or "preventing" refer to any method that partially or completely prevents, delays, or slows the onset of one or more symptoms or features of a disease, disorder, and / or condition (e.g., cancer). Prevention is the non-development of clinical symptoms of a disease state, i.e., inhibiting the onset of the disease, in a subject who may be exposed to or predisposed to a disease state, but has not yet experienced or displayed symptoms of the disease state. Prevention can be performed on a subject who does not show signs of a disease, disorder, and / or condition. In some embodiments, slowing the onset of one or more symptoms or features of a disease or disorder means that, if a recurrence of the disease or disorder or one or more symptoms of a disease or disorder occurs, the recurrence of the disease or disorder or one or more symptoms of the disease or disorder is at least about 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, or 99% slower than the recurrence of the disease or disorder or one or more symptoms of the disease or disorder in the absence of administration of YIV-906.
[0070] As used herein, the terms "subject," "patient," or "individual" to whom administration is contemplated include, but are not limited to, humans (i.e., males or females of any age group, e.g., pediatric subjects (e.g., infants, children, adolescents) or adult subjects (e.g., young adults, middle-aged adults, or elderly adults)) and / or other primates (e.g., cynomolgus monkeys, rhesus monkeys); mammals, including commercially relevant mammals such as cattle, pigs, horses, sheep, goats, cats, and / or dogs; and / or birds, including commercially relevant birds such as chickens, ducks, geese, quail, and / or turkeys.
[0071] As used herein, the term "therapeutically effective amount" refers to an amount of a compound of the present disclosure that, when administered to a patient, treats, minimizes, and / or ameliorates the symptoms of a disease or disorder. The amount of a compound of the present disclosure that constitutes a "therapeutically effective amount" will vary depending on factors such as the compound, the disease state and its severity, the age of the patient to be treated, etc. A therapeutically effective amount can be routinely determined by one of ordinary skill in the art, taking into account one's knowledge and the present disclosure.
[0072] As used herein, the term "treatment" or "treating" is defined as the application or administration of a therapeutic agent, i.e., a compound useful in the present disclosure (alone or in combination with another pharmaceutical agent) to a subject, or the application or application of a therapeutic agent to an isolated tissue or cell line from a subject suffering from cancer, symptoms of cancer, or the likelihood of developing cancer (e.g., for diagnostic or in vitro applications), with the purpose of treating, curing, alleviating, relieving, altering, remedying, improving, or affecting cancer, symptoms of cancer, or the likelihood of developing cancer. Such treatment methods can be specifically tailored or modified based on knowledge gained from the field of pharmacogenomics.
[0073] Range: Throughout the disclosure, various aspects of the disclosure may be expressed in the form of ranges. It should be understood that description in range format is for convenience and brevity only and should not be construed as an inflexible limitation on the scope of the disclosure. Therefore, descriptions of ranges should be considered to have specifically disclosed all possible subranges and individual values within the range. For example, descriptions of ranges such as 1 to 6 should be considered to specifically disclose subranges, such as 1 to 3, 1 to 4, 1 to 5, 2 to 4, 2 to 6, 3 to 6, etc., as well as integers and decimals within the range, e.g., 1, 2, 2.7, 3, 4, 5, 5.3, and 6. This applies regardless of the breadth of the range.
[0074] In addition, the numerical values expressed in range format throughout this document should be interpreted in a flexible manner to include not only the numerical values that are clearly defined as the limits of the range, but also all individual numerical values or sub-ranges contained in the range, just as if each numerical value and sub-range were explicitly stated. For example, the range of "about 0.1% to about 5%" or "about 0.1% to 5%" should be interpreted as including not only about 0.1% to about 5%, but also individual values (e.g., 1%, 2%, 3% and 4%) and sub-ranges (e.g., 0.1% to 0.5%, 1.1% to 2.2%, 3.3% to 4.4%) within the range. Unless otherwise specified, the sentence "about X to Y" has the same meaning as "about X to about Y". Similarly, unless otherwise specified, "about X, Y or about Z" has the same meaning as "about X, about Y or about Z".
[0075] In the methods described herein, actions may be performed in any order unless time or order of operations is explicitly mentioned. In addition, specific actions may be performed simultaneously unless explicit language states that they are performed separately. For example, in a single operation, a claimed action of performing X and a claimed action of performing Y may be performed simultaneously, and the resulting process will fall within the literal scope of the claimed process.
[0076] This article uses the following abbreviations:
[0077] cGMP Current Good Manufacturing Practice
[0078] CAR Chimeric Antigen Receptor
[0079] NFAT Nuclear factor of activated T cells
[0080] TCR T cell receptor
[0081] SHP2 SH2-containing phosphatase 2
[0082] SEE Staphylococcus superantigen E
[0083] G Licorice, also known as Chinese Licorice
[0084] P Paeonia lactiflora, also known as Chinese peony
[0085] S. Scutellaria baicalensis, also known as Baikal skullcap or scute
[0086] Z Golden Silk Dates, also known as red dates or Chinese dates.
[0087] YIV-906 is inspired by a traditional Chinese herbal formula and consists of four herbs: Licorice (G), Peony (P), Scutellaria (S), and Jujube (Z). Historically, YIV-906 has been used to treat gastrointestinal symptoms, including diarrhea, nausea, and vomiting. Here, a Jurkat cell-Staphylococcus superantigen E (SEE)-Raji cell cell culture model was used to demonstrate that YIV-906 can promote T cell activation by modulating nuclear factor of activated T cells (NFAT) activity, leading to CD69 upregulation. Without wishing to be bound by any theory, this may be due to YIV-906 modulating SHP2 activity, leading to increased protein phosphorylation of the T cell receptor signaling cascade, including Lck, Fyn, Zap70, LAT, and Pyk2. G, S, and their compounds have an inhibitory effect on SHP2. P, S, and their compounds can induce protein phosphorylation of the T cell receptor signaling cascade. YIV-906 S and S flavonoids were found to play a key role in modulating NFAT activity. Importantly, YIV-906 can enhance the effect of anti-PD1 to rescue the reduced NFAT activity of Jurkat cells-PD1 cells when incubated with Raji-PD-L1 cells. In addition, YIV-906 can also enhance NFAT activity triggered by the interaction of chimeric antigen receptor (CAR-CD19-CD3z) on Jurkat cells and CD19 on Raji cells. This article shows that YIV-906 and some of its components can modulate T cell activation to improve the effectiveness of immune checkpoint blockade therapy, CAR T cell therapy and vaccines.
[0088] Composition
[0089] In one aspect, the present invention provides a herbal composition for use in modulating NFAT activity in T cells in a subject in need thereof.
[0090] In certain embodiments, the composition includes the herbal extract PHY906, which includes herbal extracts of Scutellaria baicalensis (S), Glycyrrhiza uralensis (G), Paeonia lactiflora (P), and Ziziphus jujuba (Z), fractions thereof, or any active chemical substance present in the herbal extract or its fractions.
[0091] In certain embodiments, the composition comprises an herbal extract of S, a fraction thereof, or any active chemical substance present in the herbal extract or its fraction. In certain embodiments, the composition comprises an herbal extract comprising an extract of S, a fraction thereof, or any active chemical substance present in the herbal extract or its fraction.
[0092] In certain embodiments, the composition comprises an herbal extract of G, a fraction thereof, or any active chemical substance present in an herbal extract or a fraction thereof. In certain embodiments, the composition comprises an herbal extract comprising an extract of G, a fraction thereof, or any active chemical substance present in an herbal extract or a fraction thereof.
[0093] In certain embodiments, the composition comprises an herbal extract of P, a fraction thereof, or any active chemical substance present in the herbal extract or its fraction. In certain embodiments, the composition comprises an herbal extract comprising an extract of P, a fraction thereof, or any active chemical substance present in the herbal extract or its fraction.
[0094] In certain embodiments, the composition comprises an herbal extract of Z, a fraction thereof, or any active chemical substance present in an herbal extract or a fraction thereof. In certain embodiments, the composition comprises an herbal extract comprising an extract of Z, a fraction thereof, or any active chemical substance present in an herbal extract or a fraction thereof.
[0095] In certain embodiments, the composition further comprises one or more pharmaceutically acceptable carriers.
[0096] In certain embodiments, the composition is formulated in the form of a pill, tablet, capsule, decoction, tea, concentrate, lozenge, liquid, drops, or caplet for oral administration.
[0097] In certain embodiments, the composition is used to promote immune checkpoint blockade therapy for cancer treatment, promote CAR T cell therapy for cancer treatment, enhance the effectiveness of vaccination and / or as a cancer chemopreventive agent.
[0098] method
[0099] In another aspect, the present invention provides a method for enhancing NFAT activity and / or restoring suppressed NFAT activity in T cells of a subject in need. In addition, the present invention also includes a method for enhancing the efficacy of chimeric antigen receptor T cells (CAR T) immunotherapy in a subject; a method for enhancing the efficacy of immune checkpoint blockade therapy in a subject; a method for enhancing the effectiveness of a vaccine in a subject; and a method for cancer chemoprevention.
[0100] In certain embodiments, the method comprises administering to the subject an effective amount of an herbal extract PHY906, which comprises herbal extracts of Scutellaria baicalensis (S), Glycyrrhiza uralensis (G), Paeonia lactiflora (P), and Ziziphus jujuba (Z), fractions thereof, or any active chemical substance present in the herbal extract or its fractions.
[0101] In certain embodiments, the method comprises administering to a subject an effective amount of an herbal extract of S, a fraction thereof, or any active chemical substance present in an herbal extract or a fraction thereof. In certain embodiments, the method comprises administering to a subject an effective amount of an herbal extract comprising an extract of S, a fraction thereof, or any active chemical substance present in an herbal extract or a fraction thereof. In certain embodiments, the active chemical substance in the herbal extract of S or a fraction thereof is at least one selected from the group consisting of melaleucain A 7-O-β-D-glucuronide, baicalein, melaleucain A, baicalin, isomers of baicalin, chrysanthemum yellow ...
[0102] In certain embodiments, the method comprises administering to a subject an effective amount of an herbal extract of G, a fraction thereof, or any active chemical substance present in the herbal extract or its fraction. In certain embodiments, the method comprises administering to a subject an effective amount of an herbal extract comprising an extract of G, a fraction thereof, or any active chemical substance present in the herbal extract or its fraction. In certain embodiments, the active chemical substance in the herbal extract of G or its fraction is at least one selected from the group consisting of liquiritigenin, isoliquiritigenin, liquiritigenin, isoliquiritigenin, licoricechalcone A, and glycyrrhizic coumarin.
[0103] In certain embodiments, the method comprises administering to a subject an effective amount of an herbal extract of P, a fraction thereof, or any active chemical substance present in the herbal extract or its fraction. In certain embodiments, the method comprises administering to a subject an effective amount of an herbal extract comprising an extract of P, a fraction thereof, or any active chemical substance present in the herbal extract or its fraction. In certain embodiments, the active chemical substance in the herbal extract of P or its fraction is at least one selected from gallic acid, 4-o-methylpaeoniflorin, 4-o-methylpaeoniflorin isomers, 6′-O-galloylpaeoniflorin, paeoniflorin, paeoniflorin, or any combination thereof.
[0104] In certain embodiments, the method induces phosphorylation of proteins in the TCR downstream cascade and inhibits the activity of SHP2.
[0105] In certain embodiments, the methods described herein are used to improve the efficacy of anticancer agents / immunotherapeutic agents including ipilimumab, pembrolizumab, nivolumab, durvalumab, avelumab, dotalimumab-gxly, cemiplizumab-rwlc, toripalimab, carrelizumab, tislelizumab, penampalimumab, sepalimumab, sintilimab, atezolizumab, and chimeric antigen receptor T cells (CAR T cells), or any combination thereof.
[0106] In certain embodiments, the methods of the invention are used to treat cancer, e.g., melanoma, Merkel cell carcinoma (MCC), basal cell carcinoma (BCC); squamous cell carcinoma, including, e.g., head and neck squamous cell carcinoma (HNSCC), esophageal squamous cell carcinoma (ESCC), and cutaneous squamous cell carcinoma (CSCC); lymphoma, including, e.g., Hodgkin lymphoma, classical Hodgkin lymphoma (cHL), and large B-cell lymphoma; lung cancer, including, e.g., non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), and extensive-stage small cell lung cancer (ES-SCLC); CLC); liver cancer, including hepatocellular carcinoma (HCC); pancreatic cancer, renal cell carcinoma (RCC), colon cancer, colorectal cancer (CRC), mesothelioma, gastric cancer, gastroesophageal junction cancer; esophageal cancer, including esophageal adenocarcinoma; cervical cancer; endometrial cancer, including recurrent or advanced endometrial cancer with mismatch repair deficiency (dMMR); bladder cancer, including urothelial carcinoma; breast cancer, including triple-negative breast cancer (TNBC); cancers with mismatch repair (MMR) deficiency; cancers with high microsatellite instability (MSI); and cancers with high tumor mutation burden (TMB).
[0107] In certain embodiments, the method comprises orally administering to the subject the herbal extract in the form of pills, tablets, capsules, decoctions, teas, concentrates, lozenges, liquids, drops, and caplets.
[0108] In certain embodiments, the herbal composition further comprises a pharmaceutically acceptable carrier.
[0109] In certain embodiments, the therapeutically effective amount of the herbal composition is from about 20 mg / day to about 2 g / day.
[0110] In certain embodiments, the therapeutically effective amount of the herbal composition is about 1,600 mg / day.
[0111] In certain embodiments, the herbal composition is administered at a time selected from before, simultaneously with, or after administration of one or more immunotherapeutic agents or vaccines.
[0112] In certain embodiments, the subject is a mammal. In certain embodiments, the subject is a human subject.
[0113] Administration / dosage / formulation
[0114] The administration regimen may affect what constitutes an effective amount. The therapeutic formulation may be administered to a subject before or after the onset of the disease or disorder contemplated by the present invention. In addition, several separate doses and staggered doses may be administered daily or sequentially, or the dose may be a continuous infusion, or may be a bolus injection. In addition, the dosage of the therapeutic formulation may be increased or decreased in proportion as indicated by the exigencies of the therapeutic or preventive situation.
[0115] The compositions of the present disclosure can be administered to patients, preferably mammals, more preferably humans, in doses and for a time effective to treat the diseases or disorders contemplated by the present disclosure using known procedures. The effective amount of the therapeutic compound required to achieve a therapeutic effect may vary according to factors such as the disease or disorder state of the patient; the age, sex and weight of the patient; and the ability of the therapeutic compound to treat the disease or disorder contemplated in the present disclosure. The dosage regimen can be adjusted to provide the best therapeutic response. For example, several divided doses may be administered daily, or the dose may be reduced proportionally as indicated by the exigencies of the therapeutic situation. A non-limiting example of an effective dosage range for the therapeutic compounds of the present invention is about 1 to 1,000 mg / kg body weight per day. Pharmaceutical compositions useful for practicing the present disclosure may be administered to provide doses of 1 ng / kg / day and 100 mg / kg / day. One of ordinary skill in the art will be able to study the relevant factors and make decisions about the effective amount of the therapeutic compound without undue experimentation.
[0116] In particular, the selected dosage level will depend upon a variety of factors, including the activity of the particular compound employed, the time of administration, the excretion rate of the compound, the duration of the treatment, other drugs, compounds or materials used in combination with the compound, the age, sex, weight, condition, general health and prior medical history of the patient being treated, and similar factors well known in the medical arts.
[0117] A physician with ordinary skills in the art, such as an internist or veterinarian, can easily determine and prescribe the effective amount of the desired pharmaceutical composition. For example, a physician or veterinarian can start with a dose of a compound of the present disclosure employed in a pharmaceutical composition that is lower than the dose required to achieve the desired therapeutic effect, and gradually increase the dose until the desired effect is achieved.
[0118] In certain embodiments, it is advantageous to formulate the compounds in dosage unit form for ease of administration and uniformity of dosage. As used herein, dosage unit form refers to physically discrete units suited as unitary dosages for the patient to be treated; each unit containing a predetermined quantity of the therapeutic compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. The dosage unit form of the present invention is determined by and directly dependent on (a) the unique characteristics of the therapeutic compound and the specific therapeutic effect to be achieved, and (b) the limitations inherent in the art of compounding / formulating such therapeutic compounds for the treatment of the diseases or disorders contemplated by the present invention.
[0119] In certain embodiments, the compositions of the present disclosure are formulated using one or more pharmaceutically acceptable excipients or carriers. In other embodiments, the pharmaceutical compositions of the present disclosure include a therapeutically effective amount of a compound of the present disclosure and a pharmaceutically acceptable carrier. In yet other embodiments, the compound of the present disclosure is the only bioactive agent in the composition (i.e., capable of treating cancer). In yet other embodiments, the compound of the present disclosure is the only bioactive agent in the composition (i.e., capable of treating cancer).
[0120] The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyols (for example, glycerol, propylene glycol and liquid polyethylene glycol, etc.), suitable mixtures thereof and vegetable oils. For example, a coating such as lecithin can be used, and suitable fluidity can be maintained by maintaining the required particle size and using a surfactant in the case of dispersion. The effect of microorganisms can be prevented by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, etc. In many cases, isotonic agents are preferably included in the composition, such as sugar, sodium chloride or polyols, such as mannitol and sorbitol. By including an agent that delays absorption in the composition, such as aluminum monostearate or gelatin, the absorption time of the composition for injection can be extended.
[0121] In certain embodiments, the compositions of the present invention are administered to the patient at a dosage of 1-5 times per day or more. In other embodiments, the compositions of the present disclosure are administered to the patient at a dosage range including, but not limited to, once a day, once every two days, every three days to once a week, and once every two weeks. It will be apparent to those skilled in the art that the frequency of administration of the various combination compositions of the present disclosure varies from individual to individual, depending on many factors, including, but not limited to, age, the disease or disorder to be treated, sex, overall health, and other factors. Therefore, the present disclosure should not be construed as being limited to any specific dosage regimen, and the precise dosage and composition to be administered to any patient should be determined by the attending physician after considering all other factors of the patient.
[0122] The compounds and / or compositions used in the present disclosure can be in the range of about 1 mg to about 10,000 mg, about 20 mg to about 9,500 mg, about 40 mg to about 9,000 mg, about 75 mg to about 8,500 mg, about 150 mg to about 7,500 mg, about 200 mg to about 7,000 mg, about 400 mg to about 6,000 mg, about 500 mg to about 5,000 mg, about 750 mg to about 4,000 mg, about 1,000 mg to about 3,000 mg, about 1,000 mg to about 2,500 mg, about 20 mg to about 2,000 mg, and any and all whole or partial increments therebetween. In certain embodiments, the dosage of the compounds and / or compositions of the present disclosure is about 800 mg.
[0123] In certain embodiments, the present disclosure is directed to a packaged pharmaceutical composition comprising a container containing a therapeutically effective amount of a compound of the present disclosure, alone or in combination with a second agent; and instructions for using the compound to treat, prevent, or reduce one or more symptoms of a disease or disorder contemplated by the present disclosure.
[0124] The preparation can be used in combination with conventional excipients, i.e., pharmaceutically acceptable organic or inorganic carrier materials suitable for oral, parenteral, nasal, intravenous, subcutaneous, intestinal or any other suitable administration known in the art. The pharmaceutical preparation can be sterilized and, if necessary, mixed with adjuvants such as lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts that affect osmotic pressure buffers, coloring agents, flavoring agents and / or aromatic substances. They can also be combined with other active agents when necessary.
[0125] The administration route of any composition of the present disclosure includes oral, rectal, intravaginal, parenteral, oral, sublingual or topical. The compounds used in the present disclosure can be formulated for administration by any suitable route, such as oral or parenteral, such as transdermal, transmucosal (e.g., sublingual, lingual, (through) oral, (through) urethral, vaginal (e.g., transvaginal and perivaginal), nasal (intra) and (through) rectal), intravesical, intrapulmonary, intraduodenal, intragastric, intrathecal, subcutaneous, intramuscular, intradermal, intraperitoneal, intraarterial, intravenous, intrabronchial, inhalation and topical administration.
[0126] Suitable compositions and dosage forms include, for example, tablets, capsules, caplets, pills, gel capsules, lozenges, dispersions, suspensions, solutions, syrups, granules, beads, transdermal patches, gels, powders, pellets, pastes, lozenges, creams, ointments, plasters, lotions, disks, suppositories, liquid sprays for nasal or oral administration, dry powders or aerosols for inhalation, compositions and formulations for intravesical administration, etc. It should be understood that the formulations and compositions useful in the present disclosure are not limited to the specific formulations and compositions described herein.
[0127] Oral administration
[0128] For oral administration, decoctions, teas, concentrates, tablets, lozenges, liquids, drops, suppositories or capsules, caplets and gel capsules are particularly suitable. Compositions intended for oral use may be prepared according to any method known in the art, and such compositions may contain one or more preparations selected from the group of inert non-toxic pharmaceutical excipients, which are suitable for making tablets. Such excipients include, for example, inert diluents, such as lactose; granulating agents and disintegrants, such as corn starch; binders, such as starch; and lubricants, such as magnesium stearate. Tablets may be uncoated or may be coated by known techniques to achieve a delicate effect or to delay the release of the active ingredient. Preparations for oral use may also appear in the form of hard gelatin capsules, in which the active ingredient is mixed with an inert diluent.
[0129] For oral administration, the compounds of the present disclosure can be in the form of tablets or capsules prepared by conventional methods with pharmaceutically acceptable excipients, such as binders (e.g., polyvinyl pyrrolidone, hydroxypropyl cellulose or hydroxypropyl methylcellulose); fillers (e.g., corn starch, lactose, microcrystalline cellulose or calcium phosphate); lubricants (e.g., magnesium stearate, talc or silicon dioxide); disintegrants (e.g., sodium starch glycolate); or wetting agents (e.g., sodium lauryl sulfate). If desired, the tablets can be coated using suitable methods and coating materials, such as OPADRY available from Colorcon, West Point, Pa. TM Film coating systems (eg, OPADRY TMOY type, OYC type, organic enteric-coated OY-P type, aqueous enteric-coated OY-A type, OY-PM type and OPADRY TM White, 32K18400). Liquid preparations for oral administration may be in the form of solutions, syrups or suspensions. Liquid preparations may be prepared by conventional methods with pharmaceutically acceptable additives, such as suspending agents (e.g., sorbitol syrup, methylcellulose or hydrogenated edible fats); emulsifiers (e.g., lecithin or gum arabic); non-aqueous vehicles (e.g., almond oil, oily esters or ethanol); and preservatives (e.g., methylparaben or propylparaben or sorbic acid).
[0130] Granulation techniques are well known in the pharmaceutical art and are used to modify the starting powder or other particulate material of the active ingredient. The powder is usually mixed with a binder material into larger permanent free-flowing masses or granules, which is called a "granulation". For example, a "wet" granulation process using a solvent is usually characterized by combining the powder with a binder material and wetting it with water or an organic solvent under conditions that form a wet granulation, after which the solvent must be evaporated.
[0131] Melt granulation generally involves the use of a material that is solid or semisolid at room temperature (i.e., has a relatively low softening or melting point range) to facilitate the granulation of a powder or other material without substantially adding water or other liquid solvents. Low melting point solids liquefy as a binder or granulation medium when heated to a temperature within the melting point range. The liquefied solid diffuses over the surface of the powdered material in contact with it and forms a solid granulation after cooling, in which the initial materials are bound together. The resulting melt granulation can then be provided to a tablet press or packaged for the preparation of oral dosage forms. Melt granulation improves the dissolution rate and bioavailability of the active substance (i.e., drug) by forming a solid dispersion or solid solution.
[0132] U.S. Patent No. 5,169,645 discloses directly compressible wax-containing particles with improved flow characteristics. Such particles are obtained when wax is mixed with certain additives that improve flowability in a melt, then cooled and the mixture is granulated. In some embodiments, only the wax itself melts in the melt combination of wax(s) and additive(s), while in other cases, both the wax(s) and additive(s) melt.
[0133] The present disclosure also includes a multilayer tablet comprising a layer for delayed release of one or more compounds of the present disclosure and another layer for immediate release of a drug for treating a disease or disorder contemplated by the present disclosure. Using a wax / pH sensitive polymer mixture, a gastric insoluble composition can be obtained in which the active ingredient is entrapped, ensuring its delayed release.
[0134] Parenteral administration
[0135] As used herein, "parenteral administration" of a pharmaceutical composition includes any route of administration characterized by physically breaking through the tissue of the subject and administering the pharmaceutical composition through the breach of the tissue. Thus, parenteral administration includes, but is not limited to, administering the pharmaceutical composition by injection, administering the pharmaceutical composition through a surgical incision, administering the composition through a non-surgical wound of tissue penetration, and the like. Specifically, parenteral administration contemplated includes, but is not limited to, subcutaneous, intravenous, intraperitoneal, intramuscular, intrathoracic injection, and renal dialysis infusion techniques.
[0136] The preparation of the pharmaceutical composition suitable for parenteral administration includes an active ingredient combined with a pharmaceutically acceptable carrier, such as sterile water or sterile isotonic saline. This preparation can be prepared, packaged or sold in a form suitable for push injection or continuous administration. Injectable preparations can be prepared, packaged or sold in unit dosage form, such as in ampoules or multi-dose containers containing preservatives. Preparations for parenteral administration include but are not limited to suspensions, solutions, emulsions in oily or aqueous media, pastes, and implantable sustained release or biodegradable preparations. This preparation may further include one or more additional ingredients, including but not limited to suspending agents, stabilizers or dispersants. In one embodiment of the preparation for parenteral administration, the active ingredient is provided in a dry (i.e., powder or granule) form so that it is reconstructed with a suitable medium (e.g., sterile pyrogen-free water) before the composition reconstructed for parenteral administration.
[0137] Pharmaceutical compositions can be prepared, packaged or sold in the form of sterile water for injection or oily suspensions or solutions. Such suspensions or solutions can be prepared according to known techniques and, in addition to the active ingredient, may include other ingredients, such as dispersants, wetting agents or suspending agents described herein. Such sterile injectable preparations can be prepared using nontoxic parenterally acceptable diluents or solvents, such as, for example, water or 1,3-butanediol. Other acceptable diluents and solvents include, but are not limited to, Ringer's solution, isotonic sodium chloride solution, and fixed oils, such as synthetic monoglycerol or diglycerol. Other useful parenterally administrable preparations include those containing active ingredients in microcrystalline form, liposomal preparations, or as components of biodegradable polymer systems. Compositions for sustained release or implantation may include pharmaceutically acceptable polymers or hydrophobic materials, such as emulsions, ion exchange resins, slightly soluble polymers, or slightly soluble salts.
[0138] Controlled release formulations and drug delivery systems
[0139] In certain embodiments, the formulations of the present disclosure may be, but are not limited to, short-term, rapid-offset, and controlled, for example, sustained-release, delayed-release, and pulsatile-release formulations.
[0140] The term sustained release in its conventional sense refers to a pharmaceutical formulation that provides gradual release of a drug over an extended period of time and can (although not necessarily) result in substantially constant blood levels of the drug over an extended period of time. This period of time can be up to a month or more and should be a longer release than the same amount of the drug administered as a bolus.
[0141] To achieve sustained release, the compound may be formulated with an appropriate polymer or hydrophobic material that provides the compound with sustained release properties.Thus, the compounds useful in the methods of the present disclosure may be administered in the form of microparticles, such as by injection, or in the form of wafers or disks by implantation.
[0142] In one embodiment of the present disclosure, the compounds of the present disclosure are administered to a patient using a sustained release formulation, alone or in combination with another pharmaceutical formulation.
[0143] As used herein, the term delayed release refers in a conventional sense to a drug formulation that provides for initial release of the drug after a delay after administration of the drug, which delay may, though not necessarily, include from about 10 minutes up to about 12 hours.
[0144] Pulsatile release is used herein in a conventional sense to refer to a drug formulation that provides for release of the drug in a manner that produces a pulsatile plasma profile of the drug following administration of the drug.
[0145] The term immediate release is used in its conventional sense to refer to a drug formulation that releases the drug immediately after administration.
[0146] As used herein, short-term refers to any period of time after administration of a drug, up to and including about 8 hours, about 7 hours, about 6 hours, about 5 hours, about 4 hours, about 3 hours, about 2 hours, about 1 hour, about 40 minutes, about 20 minutes, about 10 minutes, or about 1 minute, and any or all of such whole or partial increments.
[0147] As used herein, rapid replenishment refers to any time period after drug administration, up to and including about 8 hours, about 7 hours, about 6 hours, about 5 hours, about 4 hours, about 3 hours, about 2 hours, about 1 hour, about 40 minutes, about 20 minutes, about 10 minutes or about 1 minute, and any and all whole or partial increments.
[0148] Drug administration
[0149] The therapeutically effective amount or dosage of the compounds of the present disclosure depends on the age and weight of the patient, the patient's current medical condition, and the progression of the disease or disorder contemplated by the present disclosure. A skilled person will be able to determine the appropriate dosage based on these and other factors.
[0150] The suitable dosage of the compound, composition or extract of the present disclosure may be in the range of about 0.01 mg to about 5,000 mg per day, such as about 0.1 mg to about 1,000 mg, for example, about 1 mg to about 500 mg per day, such as about 5 mg to about 250 mg. The dosage may be administered in a single dose or multiple doses, for example 1 to 5 times or more per day. When multiple doses are used, the amount of each dose may be the same or different. For example, a dose of 1 mg per day may be administered as two doses of 0.5 mg, with an interval of about 12 hours between each dose.
[0151] In various embodiments, the amount or dose of the herbal composition administered can be about 0.5 mg / kg to about 5000 mg / kg, about 1 mg / kg to about 2500 mg / kg, about 5 mg / kg to about 1000 mg / kg, or about 10 mg / kg to about 1000 mg / kg. In various embodiments, the amount or dose of the YIV-906 herbal extract administered can be about 0.01, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 120, 140, 160, 180, 200, 200, 220, 240, 260, 280, 300, 320, 330, 340, 350, 360, 370, 380, 390, 400, 410, 420, 430, 440, 450, 460, 470, 480, 490, 500, 510, 520, 530, 540, 550 40、360、380、400、420、440、460、480、500、520、540、560、580、600、620、640、660、680、700、720、740、760、780、800、820、840、860、880、900、920、940、960、980、1000、1020、 1040、1060、1080、1100、1120、1140、1160、1180、1200、1220、1240、1260、1280、1300、1320、1340、1360、1380、1400、1420、1440、1460、1480、1500、1520、1540、1560、1580、 1600, 1620, 1640, 1660, 1680, 1700, 1720, 1740, 1760, 1780, 1800, 1820, 1840, 1860, 1880, 1900, 1920, 1940, 1960, 1980, 2000, 2500, 3000, 3500, 4000, 4500 or about 5000 mg / kg. These amounts of the herbal extract can be administered using any of the dosing regimens described herein.
[0152] In various embodiments, the amount or dose of any immune checkpoint inhibitor or immunotherapeutic agent described herein can be about 0.01 mg / kg to about 50 mg / kg, about 0.05 mg / kg to about 30 mg / kg, or about 1 mg / kg to about 20 mg / kg. In various embodiments, the amount or dosage of any of the immune checkpoint inhibitors or immunotherapeutics described herein can be 0.01, 0.05, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 1.2, 1.4, 1.6, 1.8, 2, 2.2, 2.4, 2.6, 2.8, 3, 3.2, 3.4, 3.6, 3.8, 4, 4.2, 4.4, 4.6, 4.8, 5, 5.2, 5.4, 5.6, 5.8, 6, 6.2, 6.4, 6.6, 6.8, 7, 7.2, 7.4, 7.6, 7.8, 8, 8.2, 8.4, 8.6, 8.8, 9, 9.2, 9.4, 9.6, or about 20 mg / kg.In some embodiments, the maximum daily administration or dosage of any of the immune checkpoint inhibitors or immunotherapeutics described herein can be about 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 100, 120, 140, 160, 180, 200, 220, 240, 260, 280, 300, 320, 340, 360, 380, 400, 420, 440, 460, 480, 500, 520, 540, 560, 580, 600, 620, 640, 660, 680, 700, 720, 740, 760, 780, 800, 820, 840, 860, 880, 900, 920, 940, 960, 980, 100, 100, 120, 140, 160, 180, 200, 220, 240, 260, 280, 300, 320, 340, 360, 380, 000, 1020, 1040, 1060, 1080, 1100, 1120, 1140, 1160, 1180, 1200, 1220, 1240, 1260, 1280, 1300, 1320, 1340, 1360, 1380, 1400, 1420, 1440, 1460, 1480, 1500 , 1520, 1540, 1560, 1580, 1600, 1620, 1640, 1660, 1680, 1700, 1720, 1740, 1760, 1780, 1800, 1820, 1840, 1860, 1880, 1900, 1920, 1940, 1960, 1980 or about 2000 mg.
[0153] In some embodiments, the herbal composition and the single immunotherapeutic agent are the only therapeutically active agents in the pharmaceutical composition.
[0154] It is understood that, in non-limiting examples, the amount of compound administered daily can be administered every day, every other day, every 2 days, every 3 days, every 4 days, or every 5 days. For example, in the case of administration every other day, a daily dose of 5 mg can be initiated on Monday, the first subsequent daily dose of 5 mg can be administered on Wednesday, the second subsequent daily dose of 5 mg can be administered on Friday, etc.
[0155] In the event that the patient's condition does improve, the inhibitor of the present disclosure may optionally be administered continuously, at the discretion of the physician; alternatively, the dosage of the drug administered may be temporarily reduced or suspended for a certain length of time (i.e., a "drug holiday"). The length of the drug holiday may be selected to vary between 2 days and 1 year, including, by way of example only, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 10 days, 12 days, 15 days, 20 days, 28 days, 35 days, 50 days, 70 days, 100 days, 120 days, 150 days, 180 days, 200 days, 250 days, 280 days, 300 days, 320 days, 350 days, or 365 days. Dose reductions during drug holidays include 10%-100%, including, by way of example only, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or 100%.
[0156] Once the patient's condition improves, a maintenance dose is administered, if necessary. Subsequently, the dose or frequency of administration, or both, is reduced to a level that maintains the disease improvement as the disease or disorder progresses. In certain embodiments, the patient may require intermittent treatment on a long-term basis upon recurrence of any symptoms and / or infection.
[0157] The compounds used in the methods of the present disclosure can be formulated into unit dosage forms. The term "unit dosage form" refers to physically discrete units suitable as unit dosages for patients receiving treatment, each unit containing a predetermined amount of active substance calculated to produce the desired therapeutic effect, optionally used together with a suitable pharmaceutical carrier. The unit dosage form can be used for one of a single daily dose or multiple daily doses (e.g., about 1 to 5 times or more per day). When multiple daily doses are used, the unit dosage form of each dose can be the same or different.
[0158] The toxicity and efficacy of such treatment regimens are optionally determined in experimental animals, including but not limited to determining the LD 50 (a dose lethal to 50% of the population) and ED 50 (The dose that has a therapeutic effect on 50% of the population). The dose ratio between toxicity and efficacy is the therapeutic index, which is expressed as LD 50 and ED 50 The data obtained from animal studies are optionally used in formulating a range of dosage for use in humans. The dosage of such compounds preferably lies within a range of circulating concentrations that include the ED with minimal toxicity. 50 Within this range the dosage may vary depending upon the dosage form employed and the route of administration utilized.
[0159] Unless otherwise indicated, the practice of the present disclosure employs conventional techniques of molecular biology (including recombinant techniques), microbiology, cell biology, biochemistry and immunology, which are well within the scope of the skilled artisan. Such techniques are fully explained in the literature, for example, "Molecular Cloning: A Laboratory Manual", 2nd Edition (Sambrook, 1989); "Oligonucleotide Synthesis" (Gait, 1984); "Animal Cell Culture" (Freshney, 1987); "Methods in Enzymology" "Handbook of Experimental Immunology" (Weir, 1996); "Gene Transfer Vectors for Mammalian Cells" (Miller and Calos, 1987); "Current Protocols in Molecular Biology" (Ausubel, 1987); "PCR: The Polymerase Chain Reaction", (Mullis, 1994); "Current Protocols in Immunology" (Coligan, 1991). These techniques are applicable to the production of polynucleotides and polypeptides of the present disclosure, and therefore, may be considered in making and practicing the present disclosure. Techniques particularly useful for specific embodiments will be discussed in the following sections.
[0160] Those skilled in the art will recognize or be able to determine by routine experimentation many equivalents to the specific procedures, embodiments, claims, and examples described herein. Such equivalents are considered to be within the scope of the present disclosure and are covered by the claims appended hereto. For example, it should be understood that reaction conditions including, but not limited to, modification of reaction times, reaction sizes / volumes, and experimental reagents and art-recognized alternatives, using no more than routine experimentation, are within the scope of the present application.
[0161] It should be understood that all the numerical values and ranges provided herein are described in range format only for convenience and brevity, and should not be construed as a hard limit to the scope of the present disclosure. Therefore, all numerical values and ranges contained in these numerical values and ranges are meant to be included in the scope of the present disclosure. In addition, all numerical values falling in these ranges, as well as the upper or lower limit of the numerical range, are also considered by the present application. The description of the range should be deemed to have specifically disclosed all possible sub-ranges and single values within the range, and partial integers of the numerical values within the range are disclosed when appropriate. For example, a description of a range such as 1 to 6 should be deemed to specifically disclose sub-ranges, such as 1 to 3, 1 to 4, 1 to 5, 2 to 4, 2 to 6, 3 to 6, etc., as well as single numbers within the range, for example, 1, 2, 2.7, 3, 4, 5, 5.3 and 6. This applies no matter how large the range is.
[0162] Example
[0163] The present disclosure is further described in detail by reference to the following experimental examples. These examples are for illustrative purposes only and are not intended to be limiting unless otherwise stated. Therefore, the present disclosure should never be construed as being limited to the following examples, but should be construed as including any and all variations that become apparent due to the teachings provided herein.
[0164] Without further description, it is believed that one of ordinary skill in the art can utilize the foregoing description and the following illustrative examples to make and utilize the compounds of the present disclosure and to implement the claimed methods. Therefore, the following working examples specifically point out preferred embodiments of the present disclosure and should not be construed as limiting the remainder of the present disclosure in any way.
[0165] Methods and Materials
[0166] Preparation of herbal extracts
[0167] PHY906 consists of a traditional hot water extract of four herbs: Scutellaria baicalensis (S), Paeonia lactiflora (P), Glycyrrhiza uralensis (G), and Ziziphus jujuba (Z) in a ratio of 3:2:2:2, prepared according to standard operating procedures. This extract includes a complex mixture of phytochemicals with a variety of biological and pharmacological properties. Currently, it is not possible to identify a subset of relevant bioactive phytochemicals from the entire mixture. For this reason, a high-level chemical and biological index was used to characterize the PHY906 product.
[0168] The raw materials of PHY906 are pre-selected to meet the strict specifications accepted by Sun Ten Pharmaceuticals, a herbal medicine manufacturer in Taiwan, China, set by PhytoCeutica. The PHY906 extract consists of more than 75% low molecular weight phytochemical compounds below 1000amu, 10% macromolecular components (including proteins, nucleic acids, complex carbohydrates) and 5% water. In addition, 10% by weight of excipient insoluble cellulose is added during the spray drying step in the manufacturing. Heavy metals (Pb, Hg, Cd, As) are all below 0.5ppm, with mercury and cadmium below 0.03ppm, as detected by atomic absorption measurement. By LC-MS or GC-MS, the pesticide level (BHC, DDT, PCNB) is less than 0.2ppm. The total number of bacteria is 260cfu / g, while Escherichia coli and Salmonella species are not detected. More than 90% of PHY906 by weight can be re-extracted, excluding water content (5%) and insoluble starch excipients (10%). The final PHY906 liquid extract (100 mg / ml) was stable at room temperature for 18 hours, and the properly stored bulk dry extract (vacuum packed, protected from light, 4°C) appeared to be stable for more than three years.
[0169] LC-MS method
[0170] Chemical characterization of metabolites of PHY906 by LC-MS analysis
[0171] LC-MS analysis was performed on an Agilent 1200 series HPLC coupled to an AB SCIEX 4000QTRAP mass spectrometer. Separation was performed on an Alltima TMHP HPLC column (5 mm, 4.6 × 250 mm). The mobile phase was acetonitrile (A) and water containing 0.1% formic acid (B), with a gradient elution of: 0 min, 5% A; 10 min, 20% A; 20 min, 25% A; 40 min, 30% A; 45 min, 35% A; 55 min, 45% A; 60 min, 70% A; 62 min, 90% A; 67 min, 90% A; 68 min, 5% A; and 75 min, 5% A. The flow rate was 1.0 mL / min, and the column temperature was set at 30°C. ESI negative mode mass spectrometry with a scan rate of 4000 amu / s was performed using the following ionization parameters: CAD: high; TEM: 550.00°C; GS1: 55.00; GS2: 50.00; ihe: ON; IS: -4250.00; DP: -40.00; CES 0.00; CE: -5.00. The mass range detected was 120-800 amu. These peaks were compared using a custom program integrated with MZmine software and cluster analysis was established.
[0172] Cell lines
[0173] RPMI1640 + 5% FBS + 50ug / ml Kanamycin, 37 ° C, 5% CO2 incubation is the condition for cell culture and experiment. Jurkat (T lymphocytes) cells were transfected with pcDNA-PD1-Dyk DNA and then screened by G418 200ug / ml. Raji (B lymphocytes) cells were transfected with pcDNA-PD-L1-Dyk DNA and then screened by G418 600ug / ml. Using a laser flow cytometer (BD, Accuri 6plus), anti-PD1-PE (biolegend, #A17188B) or anti-PD-L1 (CD274)-APC (Invitrogen, #17-5983-42) was used to confirm the expression of PD1 or PD-L1 on Jurkat cells or Raji cells. Jurkat-PD1 cells were transfected with NFAT luciferase reporter DNA, in which four repeats of the NFAT response element: ggaggaaaaactgtttcatacagaaggcgt (SEQ ID NO: 1) oligo were inserted into the pGL4 vector (promega), and then selected with 0.1 ug / ml puromycin. Jurkat-PD1NFAT-lucTCRαβ knockout cells were generated using CRISPR / Cas9 technology. The targeting DNA sequences for TCRa and TCRb were CTTCAAGAGCAACAGTGCTG (SEQ ID NO: 2) and AGGTCGCTGTGTTTGAGCCA (SEQ ID NO: 3), respectively. Anti-TCRαβ (Biolegend) was used to confirm the knockout of TCRαβ. The CAR-CD19-CD3ζ vector was transfected into Jurkat-PD1 NFAT-luc, and GFP-positive cells were sorted by flow cytometry. When NFAT luciferase activity was increased by co-culture with wild-type Raji cells, the Jurka-PD1 NFAT-luc CAR-CD19-CD3ζ clone was selected.
[0174] Stimulation of NFAT in Jurkat cells
[0175] 75ul 10 6 Jurkat-PD1 cells (with or without 2x10 2Wild-type Raji cells or Raji-PD-L1 cells were seeded into round-bottom 96-well plates. In some experiments, InVivoSIM anti-human PD-1 (nivolumab biosimilar) (BioXcell, #SIM0003) 18ug / ml was added to the cells 2h or 24h before drug and SEE treatment. 25ul control medium or 25ul 5-fold concentration of YIV-906 or other drugs were added to the wells. Then 25ul SEE (ToxinTechnology, #ET404) (5×10ng / ml) was added to the wells. After incubation overnight at 37°C and 5% CO2, the cells were lysed with luciferase lysis buffer. Luciferase buffer containing luciferin was added to produce luminescence. Luminescence was recorded using a luminescence microplate reader.
[0176] Flow cytometric analysis
[0177] 4x10 cells / well in 24-well plates were treated with YIV-906 in the presence or absence of SEE (10 ng / ml and 30 ng / ml). 5 / ml 2x10 wild-type Raji cells or Raji-PD-L1 cells 5 / ml Jurkat-PD1 cells for 48h. Anti-CD69-FITC (biolegend, #310904) and anti-PD1-PE (biolegend, #A17188B) in PBS + 1% BSA were used to stain the cells. Anti-PD1-PE was used to select Jurkat-PD1 cells from mixed cells. Using a laser flow cytometer (BD, Accuri 6plus), the expression of CD69 in the FITC channel was expressed as median fluorescence or % of the total number of Jurkat cells.
[0178] Western blot analysis
[0179] 10 6 Jurkat-PD1 cells at 1000 g / ml were placed in a 24-well plate and treated with YIV-906 or its component herbs for 45 minutes. After spinning the cells at 1000 g for 10 minutes, red blood cells were lysed with 1 ml of BD solution on ice. The cells were collected after centrifugation at 1000 g for 10 minutes. 2 × 10 6 Cells were prepared with 2X protein loading buffer (Tris pH 6.8 1M, SDS 1%, glycerol, B-mercaptoethanol, bromophenol blue, distilled water). The samples were then heated to 95°C for 5 minutes to denature the proteins and then subjected to Western blotting. SDS polyacrylamide gel electrophoresis (10% Mini-Protean TGX TMPrecast protein gels, BioRad) were used to separate proteins based on their electrophoretic mobility. The protein extracts were placed in the wells of the gel, 10 μL per well. Migration was performed at 180 V for 50 min in 1X running buffer (Tris / Glycine / SDS). The transfer of proteins was performed at 75 V for 1 hour in transfer buffer (Tris-CAPS AX, methanol, SDS 10%, distilled water). Nonspecific binding sites on the PVDF membrane were blocked with blocking solution (3% milk powder and 1X TBS-T) for 30 min. The PVDF membrane was then incubated with primary antibodies against the protein of interest at 4°C overnight. The information of the primary antibodies is as follows: P-Lck-Y394 (Biolegend, #933101), P-Zap70-Y319 (Cell signaling, #2717), P-LAT-Y191 (Cell signaling, #3584) P-SRC (Fyn) Y416 (Cell signaling, #6943), P-Pyk2-Y402 (Cell signaling, 3291), GAPDH (Cell Signaling, #5174). The membrane was washed with TBS-T 1X and incubated with horseradish peroxidase-conjugated anti-rabbit IgG 1:5000 (ThermoFisher Scientific, #A27036) secondary antibody at room temperature for 1 hour to counter the immunoglobulin corresponding to the primary antibody. The membrane was washed with TBS-T 1X. Protein bands were detected using chemiluminescence (Super Signal West Dura, Thermo Scientific Cat#PI34076) and images were displayed by an X-ray film processor (Fuji Super RX-N). Densitometric scanning was performed with an Epson V600 scanner. Image-J was used to quantify the total intensity of the immunoreactive bands. GAPDH was used as an internal control for normalization.
[0180] Example 1: YIV-906 can regulate the activity of nuclear factor of activated T cells (NFAT) in T cells.
[0181] A cell culture model of Jurkat cells-Staphylococcal superantigen E (SEE)-Raji cells was established to study the effect of YIV-906 on T cell activation. In this cell culture model, Jurkat cells (T cells) were stably transfected with nuclear factor of activated T cells (NFAT) luciferase reporter gene DNA and PD1 DNA. For stimulation, Jurkat cells-PD1 cells were co-cultured overnight with wild-type Raji cells and 1ng / ml to 10ng / ml of SEE in the absence or presence of YIV-906 or its components, and YIV-906 or its components were added to the mixed cells. NFAT activity is reflected by luciferase activity as a measure of chemiluminescence. It was concluded from the above cell culture model that YIV-906 is able to activate T cells in the absence of ( Figure 1A ) or ( Figure 1B ) SEE regulated NFAT. YIV-906 in the range of 80ug / ml to 320ug / ml increased NFAT activity by 1-fold. When YIV-906 was compared with its component herbs (at their equivalent concentrations): Glycyrrhiza uralensis (G), Paeonia lactiflora (P), Scutellaria baicalensis (S), and Ziziphus jujuba (Z) on NFAT-mediated transcriptional activity in Jurkat cells, S showed very similar dose responses to YIV-906 both in the absence and presence of SEE ( Figure 1A and 1B ). G and P did not regulate NFAT activity by more than 20% in the absence or presence of SEE ( Figure 1A and 1B Z had no effect on NFAT activity ( Figure 1A and 1B When comparing two-herb combinations or three-herb combinations ( Figures 1C to 1F ), only the combination with S showed about 1-fold enhancement of NFAT activity in the absence or presence of SEE. Therefore, this paper proves that YIV-906 can regulate the activity of nuclear factor of activated T cells (NFAT) in Jurkat cells, and S plays an important role in regulating NFAT, while G and P may play a minor role in regulating NFAT.
[0182] Example 2: YIV-906 can modulate the activation of T cells that are inhibited by the interaction of PD1 and PD-L1 Activity of nuclear factor AT.
[0183] To investigate the effect of PD1-PD-L1 on NFAT activity during T cell activation, Jurkat cells-PD1 cells were co-cultured with PD-L1-overexpressing Raji cells at a ratio of 1:2 for 2 h in the absence or presence of YIV-906 or its components, and then co-cultured with 1 ng / ml to 10 ng / ml of SEE added to the mixed cells overnight. Figure 1A , 1C-1F) or PD-L1-overexpressing Raji cells ( Figure 2A , 2C-2F) had a similar effect on the basal NFAT activity of Jurkat-PD1 cells incubated with PD-1 on Jurkat cells and PD-L1 on Raji cells. The interaction between PD1 on Jurkat cells and PD-L1 on Raji cells inhibited the NFAT activity of Jurkat cells by 50% ( Figure 1B and Figure 2B YIV-906, S and the combination with S can rescue the inhibition of NFAT activity in Jurkat-PD1 cells ( Figure 2A , 2C-2F). Under the above conditions, G had a slight effect on NFAT activity ( Figures 2A-2F ).
[0184] Example 3: YIV-906 can induce the expression of CD69, a marker of T cell activation
[0185] Since YIV-906 can regulate the activity of NFAT, which is an important transcription factor for T cell activation, the effect of YIV-906 on T cell activation was further investigated by using CD69 as a T cell marker. Figures 3A-3D As shown, YIV-906 can enhance the protein expression of CD69, as evidenced by the increase in median fluorescence and percentage of CD69-highly stained population of Jurkat-PD1 cells when incubated with wild-type Raji cells without SEE or with 3 ng or 10 ng / ml SEE ( Figure 3A and 3B ). When Jurkat-PD1 cells were co-cultured with Raji-PD-L1 cells without SEE or with 3ng or 10ng / ml SEE, YIV-906 could increase CD69 expression of Jurkat-PD1 cells. Therefore, YIV-906 could modulate NFAT activity of T cells, leading to stronger T cell activation. YIV-906 could also help restore T cell activation even in the presence of PD1 and PD-L1 interaction.
[0186] Example 4: The pure compound of YIV-906 can regulate the NFAT activity of T cells.
[0187] Pure compounds present in the YIV-906 constituent herbs were selected to examine their effects on Jurkat cell NFAT ( Figures 4A-4D Among the seven compounds selected from S, melaleucatin A 7-O-β-D-glucuronide, baicalein, melaleucatin A, and chrysanthemumin could modulate the basal NFAT activity of Jurkat-PD1 cells incubated with wild-type Raji or PD-L1-overexpressing Raji cells ( Figure 5A and 5C ), however, their optimal doses were different. Melaleuca alternifolia 7-O-β-D-glucuronide required a higher dose (40uM) to achieve a 2-fold NFAT activity, while baicalin, melaleuca alternifolia A, and chrysanthemum only required 10uM to 2.5uM to produce similar effects on NFAT. In the presence of SEE, melaleuca alternifolia 7-O-β-D-glucuronide, baicalin, melaleuca alternifolia A, and chrysanthemum showed a dose-response similar to basal NFAT activity, but baicalin, melaleuca alternifolia A, and chrysanthemum could inhibit SEE-induced NFAT activity at 20 to 40uM ( Figure 5B and 5D ).
[0188] In the absence of SEE, liquiritigenin (40uM), isoliquiritigenin (10uM), liquiritigenin (20uM), isoliquiritigenin (40uM), licoricechalcone A (10-20uM), and glycyrrhizic coumarin (10uM) from G may have a certain regulatory effect on the basal NFAT activity of Jurkat-PD1 cells incubated with wild-type Raji or PD-L1-overexpressing Raji cells ( Fig. 6A and 6C In the presence of SEE, liquiritigenin (40uM), isoliquiritigenin (40uM), licoricechalcone A (10uM), and glycyrrhizic coumarin (20uM) from G could modulate the activity of NFAT up to about 30-50% of Jurkat-PD1 cells incubated with wild-type Raji or PD-L1-overexpressing Raji cells ( Figure 6B and 6D At 40uM, isoliquiritigenin and licoricechalcone showed an inhibitory effect on the NFAT activity of Jurkat cells in the presence of SEE ( Figure 6B and 6D ). Magnoflorine from Z showed an inhibitory effect on NFAT activity of Jurkat cells in the presence of SEE ( Figure 6B and 6D ).
[0189] Example 5: The effects of YIV-906, S and their components on NFAT do not require TCRαβ.
[0190] To investigate whether YIV-906 and its components can directly activate TCR activity and then lead to NFAT activation, we used CRISPR / Cas9 technology to knock out (KO) TCRαβ in Jurkat-PDA cells. Fig. 7A and 7B When Jurkat-PDATCRαβKO cells were co-cultured with wild-type Raji cells, they did not respond to SEE. Figures 7C-7F As shown in the results, YIV-906, S and S compounds (melaleuca A7-O-β-D-glucuronide, baicalin, melaleuca A and chrysin) had very similar effects on NFAT activity in Jurkat-PD1 and Jurkat-PD TCRαβKO cells. The optimal modulating doses may be different for different compounds. These results suggest that the effects of YIV-906 and its components on NFAT may bypass the TCR.
[0191] Example 6: YIV-906 and its component herbs can induce protein phosphorylation in the downstream cascade of T cell receptors
[0192] To test whether YIV-906 and its components might have direct effects downstream of the TCR, we examined the effects of YIV-906 and its components on the phosphorylation of proteins in the T cell receptor downstream cascade, including Lck, Zap70, LAT, Fyn, and Pyk2 in Jurkat cells, using Western blot analysis. Fig. 8A As shown in , treatment with 320ug / ml of YIV-906 for 45 minutes can induce phosphorylation of Lck, Zap70, LAT, Fyn, and Pyk2. By comparing the same concentration of 320ug / ml of single herbs, it was found that S and P of YIV-906 played a major role in inducing phosphorylation of the above proteins. After fractionating YIV-906 using a C18 column, relatively high activity of inducing protein phosphorylation can be found in the 60% and 15% acetonitrile / methanol (A / M) fractions ( Figure 8B ). For P, 15% A / M fraction could induce phosphorylation of all those proteins. Some activities for phosphorylation of different proteins could be found in P of water, 30%, 45%, 100% A / M fractions ( Figure 8C LCMS analysis showed that 4-o-methyl-peonidin or its isomers may exist in the P of the 15% A / M fraction ( Fig.9A ). Chemicals present in P of water, 30%, 45%, and 100% A / M fractions may also contribute to specific protein phosphorylation, as indicated by the upward red arrows ( Fig.9A For S, the major protein phosphorylation activity was found in the 45%, 60%, and 75% A / M fractions, with a certain degree of selectivity ( Fig.8D). The S in the 45% A / M fraction had a stronger effect on P-Zap70-Y319, while the S in the 60% A / M fraction had a stronger effect on P-Lck-Y39, P-LAT-Y191, P-SRC(Fyn)-Y416, and P-Pyk2-Y402 ( Fig.8D ). Fig. 9B Chemicals present in these S fractions and that may contribute to specific protein phosphorylation are listed in Fig. 9B These chemicals of P and S may have different selectivity for their targets.
[0193] Example 7: S and P compounds can induce phosphorylation of proteins in the downstream cascade of T cell receptors
[0194] Western blot analysis was used to examine the ability of some chemicals of S or P to induce phosphorylation of proteins in the T cell receptor downstream cascade, including Lck, Zap70, LAT, Fyn, and Pyk2 in Jurkat cells. 40uM baicalein could strongly induce phosphorylation of all proteins examined ( Fig.10 ). Baicalin and melaleuca alternifolia A7-O-β-D-glucuronide (OA-7-S) showed a certain induction effect on P-Zap70-Y319, P-SRC(Fyn)-Y416 and P-Pyk2-Y402 at 40uM ( Fig.10 Albiforin and Paeoniforin have certain effects on inducing P-Zap70-Y319 and P-Pyk2-Y402 ( Fig.10 ). These compounds have the potential to activate T cells by stimulating the downstream cascade of TCR.
[0195] Example 8: YIV-906 can regulate SHP2 activity in T cells
[0196] SHP2 (SH2-containing phosphatase 2, a protein tyrosine phosphatase) is immediately downstream of PD1. Once PD1 binds to PD-L1, PD-1 phosphorylates its immunoreceptor tyrosine-based inhibitory motif (ITIM) and immunoreceptor tyrosine-based switch motif (ITSM) to recruit and activate SHP2. Activated SHP2 initiates T cell inactivation by dephosphorylating TCR downstream cascade proteins such as Zap70. Inhibitors have the potential to promote T cell activation and improve cancer treatment by blocking the action of PD1. Fig.11A As shown, YIV-906 showed an inhibitory effect on the activity of the SHP2 enzyme. It was found that G and S of YIV-906 are the key herbs responsible for inhibiting SHP2 ( Fig. 11B The inhibitory effects of glycyrrhizic acid and glycyrrhetinic acid from G on SHP2 were relatively higher than those of other G compounds ( Fig. 11CBaicalin, baicalin A7-O-β-D-glucuronide, baicalin, baicalin, chrysanthemum, and baicalin A from S have an inhibitory effect on SHP2 ( Fig.11D ).
[0197] Example 9: YIV-906 can further enhance the effect of anti-PD1 antibodies to promote NFAT activity of T cells
[0198] Since YIV-906 can enhance the anti-tumor activity of anti-PD1 against tumors in animal models, it was analyzed whether YIV-906 can cooperate with anti-PD1 to promote NFAT activity to activate T cells. As mentioned above, co-culturing Jurkat-PD1 cells and Raji-PD-L1 cells with SEE 10ng / ml or 30ng / ml inhibited the NFAT activity of Jurkat cells by 50%, compared with the NFAT activity displayed by Jurkat-PD1 cells and wild-type Raji cells. YIV-906 and anti-PD1 (antibody produced by nivolumab clone) rescued the suppressed NFAT activity in Jurkat-PD1 cells (due to the interaction between PD1 and PD-L1) Fig. 12A and 12B In combination, YIV-906 did not include the effect of anti-PD1, whereas YIV-906 and anti-PD1 induced stronger NFAT activity in Jurkat PD1 cells ( Fig. 12A and 12B ). Therefore, YIV-906 has the potential to enhance immune checkpoint blockade therapy to treat cancer.
[0199] Example 10: YIV-906 can regulate NFAT activity of T cells primed by chimeric antigen receptors
[0200] It is well known that the MHC-antigen-TCR interaction will recruit the CD3 receptor to transduce the signal to NFAT. The chimeric antigen receptor (CAR) consists of an antigen recognition domain, an extracellular hinge region, a transmembrane domain, and a co-stimulatory domain such as the immunoreceptor tyrosine-based activation motif (ITAM) of CD3ζ (zeta). Once the chimeric antigen receptor (CAR) binds to its target, the signal is transferred to the ITAM of CD3ζ, which further stimulates its downstream cascade, leading to the activation of NFAT. Since MHC-antigen-TCR interaction or CAR-target interaction has the same downstream cascade for NFAT activation, and YIV-906 has the potential to enhance the NFAT response triggered by MHC-antigen-TCR, it has been questioned whether YIV-906 can also regulate NFAT activity triggered by CAR. Jurkat-PD1 NFAT luciferase receptor cells were stably transfected with CAR-CD19-CD3ζ(zeta) DNA, which expresses a CAR targeting CD19. NFAT activity can be stimulated by co-cultured Jurkat-PD1-CAR-CD19-CD3ζ and Raji, which naturally expresses CD19 on the cell surface.
[0201] like Figures 13A-13B As shown, YIV-906, S and S compounds (melaleucain A 7-O-β-D-glucuronide, baicalin, melaleucain A and chrysin) had very similar effects on NFAT activity in Jurkat-PD1 CAR-CD19 cells and Jurkat-PD1 cells. When Jurkat-PD1 CAR-CD19 cells were co-cultured with Raji, NFAT activity could be induced about 40-fold. Under these conditions, YIV-906, S and S compounds (melaleucain A 7-O-β-D-glucuronide, baicalin, melaleucain A and chrysin) could modulate NFAT activity triggered by the interaction between the chimeric antigen receptor (CAR-CD19-CD3ζ) on Jurkat cells and CD19 on Raji cells ( Figures 13C to 13D The interaction between PD1 and PD-L1 can inhibit the NFAT activity triggered by the interaction between the chimeric antigen receptor (CAR-CD19-CD3ζ) on Jurkat cells and CD19 on Raji cells ( Figures 13E-13F ), while YIV-906, S and S compounds (melaleuca A 7-O-β-D-glucuronide, baicalin, baicalein, melaleuca A and chrysanthemum) could restore this suppressed NFAT activity ( Fig.13F ). The optimal modulation doses for different compounds may be different. These results suggest that YIV-906 and its components have the potential to advance CAR T cell therapy for the treatment of cancer.
[0202] Embodiment 11:
[0203] In summary, YIV-906 can regulate NFAT activity of T cells by inhibiting SHP2 and inducing phosphorylation of TCR downstream proteins. Multiple herbs are involved: G, P, S and their compounds, and they may have different targets with different potencies. It is shown here that YIV-906 and some of its components can be used to regulate the activation of T cells to promote immune checkpoint blockade therapy or CAR T cell therapy to treat cancer in patients. Since T cell activation is a very critical step for vaccines to elicit immune responses, YIV-906 and some of its components can also be used as adjuvants to improve the effectiveness of vaccination.
[0204] Examples of implementation methods
[0205] The following enumerated embodiments are provided, the numbering of which should not be construed as designating a level of importance.
[0206] Embodiment 1 provides a method for enhancing nuclear factor of activated T cells (NFAT) activity and / or restoring suppressed NFAT activity in a subject in need thereof, wherein the method comprises administering to the subject a therapeutically effective amount of at least one herbal composition selected from the following:
[0207] (a) herbal extract PHY906, which comprises herbal extracts of Scutellaria baicalensis (S), Glycyrrhiza uralensis (G), Paeonia lactiflora (P) and Ziziphus jujuba (Z), fractions thereof or any active chemical substance present in the herbal extract or its fractions;
[0208] (b) an herbal extract of S, a fraction thereof or any active chemical substance present in an herbal extract or a fraction thereof;
[0209] (c) herbal extracts including extracts of S, fractions thereof or any active chemical substance present in herbal extracts or fractions thereof;
[0210] (d) the herbal extract of G, its fractions or any active chemical substance present in the herbal extract or its fractions;
[0211] (e) herbal extracts including extracts of G, fractions thereof or any active chemical substance present in herbal extracts or fractions thereof;
[0212] (f) an herbal extract of P, a fraction thereof or any active chemical substance present in an herbal extract or a fraction thereof; and
[0213] (g) herbal extracts including extracts of P, fractions thereof or any active chemical substance present in the herbal extract or its fractions.
[0214] Embodiment 2 provides the method of embodiment 1, wherein the active chemical substance in the herbal extract of S or its fraction is at least one selected from baicalin A 7-O-β-D-glucuronide, baicalein, baicalin A, baicalin, isomers of baicalin, chrysanthemumin 6-C-arabinoside 8-C-glucoside, actiside, baicalein I 2'-O-glucoside and chrysanthemum.
[0215] Embodiment 3 provides the method of embodiments 1-2, wherein the active chemical substance in the herbal extract of G or its fraction is at least one selected from liquiritigenin, isoliquiritigenin, liquiritigenin, isoliquiritigenin, licorice chalcone A and glycyrrhizic coumarin.
[0216] Embodiment 4 provides the method of embodiments 1-3, wherein the active chemical substance in the herbal extract of P or its fraction is at least one selected from gallic acid, 4-o-methylpaeoniflorin, 4-o-methylpaeoniflorin isomers, 6′-O-galloylpaeoniflorin, paeoniflorin and paeoniflorin.
[0217] Embodiment 5 provides the method of embodiments 1-4, wherein the herbal composition is orally administered to the subject.
[0218] Embodiment 6 provides the method of embodiments 1-5, wherein the herbal composition is formulated as one selected from the group consisting of pills, tablets, capsules, soups, teas, concentrates, lozenges, liquids, drops, and caplets.
[0219] Embodiment 7 provides the method of embodiments 1-6, wherein the therapeutically effective amount of the herbal composition is from about 20 mg / day to about 2 g / day.
[0220] Embodiment 8 provides the method of embodiments 1-7, wherein the therapeutically effective amount of the herbal composition is about 1,600 mg / day.
[0221] Embodiment 9 provides the method of embodiments 1-8, wherein the method induces phosphorylation of proteins in the downstream cascade of the T cell receptor (TCR) and inhibits the activity of SH2-containing phosphatase 2 (SHP2).
[0222] Embodiment 10 provides the method described in embodiments 1-9, wherein the herbal composition is administered at a time selected from before, simultaneously with, and after administration of immune checkpoint inhibitor therapy or chimeric antigen receptor T (CAR T) cell therapy or a vaccine.
[0223] Embodiment 11 provides the method described in embodiments 1-10, wherein the immune checkpoint inhibitor therapy comprises administering at least one immune checkpoint inhibitor selected from ipilimumab, pembrolizumab, nivolumab, durvalumab, avelumab, dotalimumab-gxly, cemiplizumab-rwlc, toripalizumab, carrelizumab, tislelizumab, penampalimumab, sepalizumab, sintilimab and atezolizumab.
[0224] Embodiment 12 provides the method of embodiments 1-11, wherein the method is advantageous for at least one selected from the following:
[0225] a) Enhance the efficacy of CAR T cell therapy,
[0226] b) enhance the efficacy of immune checkpoint inhibitor therapy, and
[0227] c) Enhance the effectiveness of vaccines.
[0228] Embodiment 13 provides the method of embodiments 1-12, wherein the method is used for cancer chemoprevention.
[0229] Embodiment 14 provides a method of enhancing the efficacy of chimeric antigen receptor T cell (CAR T) immunotherapy in a subject, wherein the method comprises administering to the subject a therapeutically effective amount of at least one herbal composition selected from the following:
[0230] (a) herbal extract PHY906, which comprises herbal extracts of Scutellaria baicalensis (S), Glycyrrhiza uralensis (G), Paeonia lactiflora (P) and Ziziphus jujuba (Z), fractions thereof or any active chemical substance present in the herbal extract or its fractions;
[0231] (b) an herbal extract of S, a fraction thereof or any active chemical substance present in an herbal extract or a fraction thereof;
[0232] (c) herbal extracts including extracts of S, fractions thereof or any active chemical substance present in herbal extracts or fractions thereof;
[0233] (d) the herbal extract of G, its fractions or any active chemical substance present in the herbal extract or its fractions;
[0234] (e) herbal extracts including extracts of G, fractions thereof or any active chemical substance present in herbal extracts or fractions thereof;
[0235] (f) an herbal extract of P, a fraction thereof or any active chemical substance present in an herbal extract or a fraction thereof; and
[0236] (g) herbal extracts including extracts of P, fractions thereof or any active chemical substance present in the herbal extract or its fractions.
[0237] Embodiment 15 provides a method for enhancing the efficacy of immune checkpoint blockade therapy in a subject, wherein the method comprises administering to the subject a therapeutically effective amount of at least one herbal composition selected from the following:
[0238] (a) herbal extract PHY906, which comprises herbal extracts of Scutellaria baicalensis (S), Glycyrrhiza uralensis (G), Paeonia lactiflora (P) and Ziziphus jujuba (Z), fractions thereof or any active chemical substance present in the herbal extract or its fractions;
[0239] (b) an herbal extract of S, a fraction thereof or any active chemical substance present in an herbal extract or a fraction thereof;
[0240] (c) herbal extracts including extracts of S, fractions thereof or any active chemical substance present in herbal extracts or fractions thereof;
[0241] (d) the herbal extract of G, its fractions or any active chemical substance present in the herbal extract or its fractions;
[0242] (e) herbal extracts including extracts of G, fractions thereof or any active chemical substance present in herbal extracts or fractions thereof;
[0243] (f) an herbal extract of P, a fraction thereof or any active chemical substance present in an herbal extract or a fraction thereof; and
[0244] (g) herbal extracts including extracts of P, fractions thereof or any active chemical substance present in the herbal extract or its fractions.
[0245] Embodiment 16 provides a method of enhancing the effectiveness of a vaccine in a subject, wherein the method comprises administering to the subject a therapeutically effective amount of at least one herbal composition selected from:
[0246] (a) herbal extract PHY906, which comprises herbal extracts of Scutellaria baicalensis (S), Glycyrrhiza uralensis (G), Paeonia lactiflora (P) and Ziziphus jujuba (Z), fractions thereof or any active chemical substance present in the herbal extract or its fractions;
[0247] (b) an herbal extract of S, a fraction thereof or any active chemical substance present in an herbal extract or a fraction thereof;
[0248] (c) herbal extracts including extracts of S, fractions thereof or any active chemical substance present in herbal extracts or fractions thereof;
[0249] (d) the herbal extract of G, its fractions or any active chemical substance present in the herbal extract or its fractions;
[0250] (e) herbal extracts including extracts of G, fractions thereof or any active chemical substance present in herbal extracts or fractions thereof;
[0251] (f) an herbal extract of P, a fraction thereof or any active chemical substance present in an herbal extract or a fraction thereof; and
[0252] (g) herbal extracts including extracts of P, fractions thereof or any active chemical substance present in the herbal extract or its fractions.
[0253] Embodiment 17 provides the method of embodiments 1-16, wherein the subject is a mammal.
[0254] Embodiment 18 provides the method described in embodiments 1-17, wherein the subject is a human subject.
[0255] Embodiment 19 provides a herbal composition for modulating NFAT activity in T cells of a subject in need thereof, wherein the composition comprises at least one selected from the group consisting of:
[0256] (a) herbal extract PHY906, which comprises herbal extracts of Scutellaria baicalensis (S), Glycyrrhiza uralensis (G), Paeonia lactiflora (P) and Ziziphus jujuba (Z), fractions thereof or any active chemical substance present in the herbal extract or its fractions;
[0257] (b) an herbal extract of S, a fraction thereof or any active chemical substance present in an herbal extract or a fraction thereof;
[0258] (c) herbal extracts including extracts of S, fractions thereof or any active chemical substance present in herbal extracts or fractions thereof;
[0259] (d) the herbal extract of G, its fractions or any active chemical substance present in the herbal extract or its fractions;
[0260] (e) herbal extracts including extracts of G, fractions thereof or any active chemical substance present in herbal extracts or fractions thereof;
[0261] (f) an herbal extract of P, a fraction thereof or any active chemical substance present in an herbal extract or a fraction thereof;
[0262] (g) herbal extracts including extracts of P, fractions thereof or any active chemical substance present in herbal extracts or fractions thereof;
[0263] (h) an herbal extract of Z, a fraction thereof or any active chemical substance present in an herbal extract or a fraction thereof; and
[0264] (i) an herbal extract comprising an extract of Z, a fraction thereof or any active chemical substance present in the herbal extract or its fraction.
[0265] Embodiment 20 provides the composition of embodiment 19, wherein the herbal composition is orally administered to the subject.
[0266] Embodiment 21 provides the composition of embodiments 19-20, wherein the herbal composition is formulated as one selected from the group consisting of pills, tablets, capsules, decoctions, teas, concentrates, lozenges, liquids, drops, and caplets.
[0267] Embodiment 22 provides the composition of embodiments 19-21, wherein the composition further comprises a pharmaceutically acceptable carrier.
[0268] Other Implementations
[0269] The recitation of the listed elements in any definition of a variable herein includes the definition of that variable as any single element or combination (or subcombination) of the listed elements. The recitation of an embodiment herein includes that embodiment as any single embodiment or in combination with any other embodiment or portion thereof.
[0270] The disclosure of each patent, patent application and publication cited herein is hereby incorporated by reference in its entirety. Although the present disclosure is made with reference to specific embodiments, it is apparent that other embodiments and variations of the present disclosure may be designed by other persons skilled in the art without departing from the true spirit and scope of the present disclosure. The appended claims are intended to be interpreted as including all such embodiments and equivalent variations.
Claims
1. A method for enhancing nuclear factor of activated T cells (NFAT) activity and / or restoring suppressed NFAT activity in a subject in need thereof, wherein the method comprises administering to the subject a therapeutically effective amount of at least one herbal composition selected from the group consisting of: (a) herbal extract PHY906, which comprises herbal extracts of Scutellaria baicalensis (S), Glycyrrhiza uralensis (G), Paeonia lactiflora (P) and Ziziphus jujuba (Z), fractions thereof or any active chemical substance present in the herbal extract or its fractions; (b) an herbal extract of S, a fraction thereof or any active chemical substance present in an herbal extract or a fraction thereof; (c) herbal extracts including extracts of S, fractions thereof or any active chemical substance present in herbal extracts or fractions thereof; (d) the herbal extract of G, its fractions or any active chemical substance present in the herbal extract or its fractions; (e) herbal extracts including extracts of G, fractions thereof or any active chemical substance present in herbal extracts or fractions thereof; (f) an herbal extract of P, a fraction thereof or any active chemical substance present in an herbal extract or a fraction thereof; and (g) herbal extracts including extracts of P, fractions thereof or any active chemical substance present in the herbal extract or its fractions.
2. The method according to claim 1, wherein the active chemical substance in the herbal extract of S or its fraction is at least one selected from the group consisting of baicalin A 7-O-β-D-glucuronide, baicalein, baicalin A, baicalin, isomers of baicalin, chrysanthemumin 6-C-arabinoside 8-C-glucoside, actiside, baicalein I 2'-O-glucoside and chrysanthemum.
3. The method according to claim 1, wherein the active chemical substance in the herbal extract of G or its fraction is at least one selected from the group consisting of liquiritigenin, isoliquiritigenin, liquiritigenin, isoliquiritigenin, licoricechalcone A and glycyrrhizic coumarin.
4. The method according to claim 1, wherein the active chemical substance in the herbal extract of P or its fraction is at least one selected from gallic acid, 4-o-methylpaeoniflorin, 4-o-methylpaeoniflorin isomers, 6′-O-galloylpaeoniflorin, paeoniflorin and paeoniflorin.
5. The method of claim 1, wherein the herbal composition is administered orally to the subject.
6. The method of claim 1, wherein the herbal composition is formulated as one selected from the group consisting of pills, tablets, capsules, decoctions, teas, concentrates, lozenges, liquids, drops and caplets.
7. The method of claim 1, wherein the therapeutically effective amount of the herbal composition is from about 20 mg / day to about 2 g / day.
8. The method of claim 7, wherein the therapeutically effective amount of the herbal composition is about 1,600 mg / day.
9. The method of claim 1, wherein the method induces phosphorylation of proteins in the downstream cascade of T cell receptor (TCR) and inhibits the activity of SH2-containing phosphatase 2 (SHP2).
10. The method of claim 1, wherein the herbal composition is administered at a time selected from before, simultaneously with, and after administration of immune checkpoint inhibitor therapy or chimeric antigen receptor T (CAR T) cell therapy or a vaccine.
11. The method of claim 10, wherein the immune checkpoint inhibitor therapy comprises administering at least one immune checkpoint inhibitor selected from ipilimumab, pembrolizumab, nivolumab, durvalumab, avelumab, dotalimumab-gxly, cemiplizumab-rwlc, toripalimab, carrelizumab, tislelizumab, penampalimumab, sepalizumab, sintilimab, and atezolizumab.
12. The method according to claim 10, wherein the method is advantageous for at least one selected from the group consisting of: a) Enhance the efficacy of CAR T cell therapy, b) enhance the efficacy of immune checkpoint inhibitor therapy, and c) Enhance the effectiveness of vaccines.
13. The method of claim 1, wherein the method is used for cancer chemoprevention.
14. A method of enhancing the efficacy of chimeric antigen receptor T cell (CAR T) immunotherapy in a subject, wherein the method comprises administering to the subject a therapeutically effective amount of at least one herbal composition selected from: (a) herbal extract PHY906, which comprises herbal extracts of Scutellaria baicalensis (S), Glycyrrhiza uralensis (G), Paeonia lactiflora (P) and Ziziphus jujuba (Z), fractions thereof or any active chemical substance present in the herbal extract or its fractions; (b) an herbal extract of S, a fraction thereof or any active chemical substance present in an herbal extract or a fraction thereof; (c) herbal extracts including extracts of S, fractions thereof or any active chemical substance present in herbal extracts or fractions thereof; (d) the herbal extract of G, its fractions or any active chemical substance present in the herbal extract or its fractions; (e) herbal extracts including extracts of G, fractions thereof or any active chemical substance present in herbal extracts or fractions thereof; (f) an herbal extract of P, a fraction thereof or any active chemical substance present in an herbal extract or a fraction thereof; and (g) herbal extracts including extracts of P, fractions thereof or any active chemical substance present in the herbal extract or its fractions.
15. A method of enhancing the efficacy of immune checkpoint blockade therapy in a subject, wherein the method comprises administering to the subject a therapeutically effective amount of at least one herbal composition selected from: (a) herbal extract PHY906, which comprises herbal extracts of Scutellaria baicalensis (S), Glycyrrhiza uralensis (G), Paeonia lactiflora (P) and Ziziphus jujuba (Z), fractions thereof or any active chemical substance present in the herbal extract or its fractions; (b) an herbal extract of S, a fraction thereof or any active chemical substance present in an herbal extract or a fraction thereof; (c) herbal extracts including extracts of S, fractions thereof or any active chemical substance present in herbal extracts or fractions thereof; (d) the herbal extract of G, its fractions or any active chemical substance present in the herbal extract or its fractions; (e) herbal extracts including extracts of G, fractions thereof or any active chemical substance present in herbal extracts or fractions thereof; (f) an herbal extract of P, a fraction thereof or any active chemical substance present in an herbal extract or a fraction thereof; and (g) herbal extracts including extracts of P, fractions thereof or any active chemical substance present in the herbal extract or its fractions.
16. A method of enhancing the effectiveness of a vaccine in a subject, wherein the method comprises administering to the subject a therapeutically effective amount of at least one herbal composition selected from: (a) herbal extract PHY906, which comprises herbal extracts of Scutellaria baicalensis (S), Glycyrrhiza uralensis (G), Paeonia lactiflora (P) and Ziziphus jujuba (Z), fractions thereof or any active chemical substance present in the herbal extract or its fractions; (b) an herbal extract of S, a fraction thereof or any active chemical substance present in an herbal extract or a fraction thereof; (c) herbal extracts including extracts of S, fractions thereof or any active chemical substance present in herbal extracts or fractions thereof; (d) the herbal extract of G, its fractions or any active chemical substance present in the herbal extract or its fractions; (e) herbal extracts including extracts of G, fractions thereof or any active chemical substance present in herbal extracts or fractions thereof; (f) an herbal extract of P, a fraction thereof or any active chemical substance present in an herbal extract or a fraction thereof; and (g) herbal extracts including extracts of P, fractions thereof or any active chemical substance present in the herbal extract or its fractions.
17. The method of any one of claims 1 and 14-16, wherein the subject is a mammal.
18. The method of claim 17, wherein the subject is a human subject.
19. An herbal composition for use in modulating NFAT activity in T cells of a subject in need thereof, wherein the composition comprises at least one selected from the group consisting of: (a) herbal extract PHY906, which comprises herbal extracts of Scutellaria baicalensis (S), Glycyrrhiza uralensis (G), Paeonia lactiflora (P) and Ziziphus jujuba (Z), fractions thereof or any active chemical substance present in the herbal extract or its fractions; (b) an herbal extract of S, a fraction thereof or any active chemical substance present in an herbal extract or a fraction thereof; (c) herbal extracts including extracts of S, fractions thereof or any active chemical substance present in herbal extracts or fractions thereof; (d) the herbal extract of G, its fractions or any active chemical substance present in the herbal extract or its fractions; (e) herbal extracts including extracts of G, fractions thereof or any active chemical substance present in herbal extracts or fractions thereof; (f) an herbal extract of P, a fraction thereof or any active chemical substance present in an herbal extract or a fraction thereof; (g) herbal extracts including extracts of P, fractions thereof or any active chemical substance present in herbal extracts or fractions thereof; (h) an herbal extract of Z, a fraction thereof or any active chemical substance present in an herbal extract or a fraction thereof; and (i) an herbal extract comprising an extract of Z, a fraction thereof or any active chemical substance present in the herbal extract or its fraction.
20. The composition of claim 19, wherein the herbal composition is administered orally to the subject.
21. The composition according to claim 19, wherein the herbal composition is formulated as one selected from the group consisting of pills, tablets, capsules, decoctions, teas, concentrates, lozenges, liquids, drops and caplets.
22. The composition of claim 19, wherein the composition further comprises a pharmaceutically acceptable carrier.
